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Abstract
IMPACT OF E-CIGARETTES ON PHYSICIAN RECOMMENDATIONS OF TOBACCO
USE CESSATION PHARMACOTHERAPY
By Omar El Shahawy, MBBCh, MPH
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2015.
Major Director: Jennifer Elston Lafata, Ph.D.
Professor, Department of Social and Behavioral Health
Introduction: E-cigarettes have been marketed as smoking cessation aids and harm reduction
strategies. Prior regional surveys found that physicians are recommending them to patients
despite the lack of evidence supporting these industry claims. Yet, little is known about
physicians’ beliefs regarding e-cigarettes and whether these beliefs are associated with them
recommending e-cigarette use in clinical practice. Methods: This three-manuscript dissertation
used a mixed-methods approach including both qualitative and quantitative research methods.
The aims were to: (1) Uncover the factors associated with primary care physicians’ (PCPs)
decisions to recommend e-cigarettes to their patients for tobacco use cessation; (2) Estimate the
prevalence of PCPs who recommend e-cigarettes to their patients as a tobacco use cessation aid;
(3) Estimate the influence of factors identified in Aim 1 on PCPs’ decisions to recommend ecigarettes to their patients for tobacco use cessation; (4) Evaluate the conceptual model which
demonstrates the factors contributing to PCPs’ decisions to recommend e-cigarettes to their
patients for tobacco use cessation. Results: Study 1 found that PCPs expressed a lack of
information about e-cigarette safety and efficacy along with skepticism about the role of ecigarettes in tobacco control in general and in smoking cessation in particular. However, once a

patient initiates a discussion with them, PCPs seem to be endorsing patients’ interests in using ecigarettes, as well as recommending e-cigarettes to particular types of patients who smoke for
both smoking cessation and as a harm reduction strategy. Study 2 found that over three-quarters
(82.7%, n=220) of PCPs reported previously discussing e-cigarettes with their patients. Overall,
57.8% (n=155) reported previously recommending e-cigarettes to an adult patient who smoked.
Among those recommending e-cigarettes, the majority reported recommending them for
smoking cessation and harm reduction (71.6%, n=111), 18.8% for smoking cessation only, and
9.6% for harm reduction only. The likelihood of recommending e-cigarettes to patients was
associated with considering their patients’ interest in using e-cigarettes, PCP’s belief that ecigarettes can help in quitting smoking, and PCP’s belief that e-cigarettes limit secondhand
smoke exposure for others. Study 3 found that PCPs intend to recommend e-cigarettes for
smokers with prior unsuccessful quit attempts (mean=3.63, ±2.1), followed by heavy smokers
wanting to quit (3.57, ±2.2), and heavy smokers refusing to quit (mean=3.50, ±2.2). The mean
for PCPs’ recommendation intentions was 3.04 (±2.0) for light smokers wanting to quit, and 3.01
(±1.9) for light smokers refusing to quit. Nevertheless, these recommendation intentions were
driven by PCPs’ beliefs and perceptions of e-cigarette benefit and harm; however, these
intentions varied by patients’ tobacco use profile. Discussion: Findings across the three studies
highlight the significance of PCPs’ beliefs in driving their recommendations of e-cigarettes
versus evidence based knowledge, as well as, the importance of patients’ factors and interest in
using e-cigarettes for PCPs’ recommendations for e-cigarette use.

Chapter 1: Introduction
Tremendous strides have been made in the United States (US) to control tobacco-related
morbidity and mortality.1 Nonetheless, a wide range of new and emerging tobacco products (See
Table 1), are thriving that may threaten these achievements .2 These products are being mostly
marketed as “alternative” products to conventional cigarettes that are well known by the US
public to be very harmful.2-4 Some of these products burn or heat tobacco (i.e. combustible) and
others are non-combustible products; both promise to reduce or eliminate the associated risk of
conventional cigarettes and can subsequently mislead US consumers to believe that safe tobacco
or nicotine use is currently possible.5
Table 1: Descriptions of Different Classes of New and Emerging Tobacco Products
o
o
o

o

o

o
o

Chewing tobacco - Any leaf tobacco that is not intended to be smoked.
Cigars - Any roll of tobacco wrapped in tobacco leaves or in any substance containing tobacco
(other than any roll of tobacco which is a cigarette).
Dissolvable Tobacco (known as “hard snuff”) – A tobacco product made from tobacco that
dissolves away in your mouth and provides the same tobacco satisfaction as cigarettes or
smokeless tobacco.
Electronic Nicotine Delivery Device ( known as “Electronic Cigarette”)– A unit comprised of a
battery, an atomizer, and a cartridge that contains a liquid to be vaporized which is inhaled and
exhaled, mimicking the action of smoking. The liquid often contains nicotine.
Hookah/Waterpipe – Although known by many different names (e.g., hookah, narghile, shisha),
the term waterpipe has been used for the last two decades in the English language scientific
literature to refer to any of a variety of instruments that involve passing tobacco smoke through
water before inhalation.
Snuff - Any finely cut, ground, or powdered tobacco that is not intended to be smoked.
Snus - A moist powder tobacco product originated from a variant of dry snuff, in the early 19th
century in Sweden, consumed by placing it under the lip for extended periods of time. Snus is a
form of snuff that is used in a manner similar to American dipping tobacco, but typically does not
result in the need for spitting. Snus is also unique in that it is steam-cured rather than fire-cured, is
not fermented and contains no added sugar.
Adapted: Barry et al, 2010

The current study focuses on the most recently introduced product in 2007,6 which is
rather a class of products called electronic nicotine delivery devices or e-cigarettes, which share
1

some common features.7, 8 These features include being battery-powered, converting nicotinecontaining liquid into a vapor that can be inhaled, and producing white vapor upon exhalation
(called vaping). Some e-cigarettes further mimic the conventional cigarette by having an LED
that illuminates during use.7, 9 Due to a lack of marketing restrictions and the availability of ecigarette producers, including major tobacco companies, e-cigarettes have evolved rapidly to
become one of the fastest growing classes of nicotine containing products in the US. 10 In fact,
the sales of e-cigarettes are projected to surpass that of conventional cigarettes by the year
2021.11 Further, the first generation e-cigarettes were not efficient in delivering nicotine.12 Since
the nicotine yield of e-cigarettes varies by design, e-cigarette nicotine concentration and other
technical features, e-cigarettes have currently progressed to their third generation (called e-mods)
undergoing a series of changes in all the aforementioned technical features. As such, they have
become much more efficient in delivering nicotine than conventional cigarettes.8, 12-14
As evidenced by a number of research studies, e-cigarette experimentation, use, and
promotion have been growing exponentially over the past few years.6, 15-17 E-cigarette
advertisements often target tobacco users with the claim that e-cigarettes can facilitate tobacco
use cessation or provide a way to smoke without restrictions, and they often offer a “free trial” to
make them more appealing.3 In other words, manufacturers are relentless in their promotion of ecigarettes as safe alternative to conventional cigarettes or as a smoking cessation aid.14,15
Moreover, the e-cigarettes industry has been spending a substantial amount of money on
advertising 18 that often targets youth and young adults.19 Thus, on the US national level,
younger individuals generally seem to be more susceptible to e-cigarette use than older
individuals, irrespective of their smoking status.20-22 In fact, teen use of e-cigarettes surpassed
that of any other tobacco product in the US in 2014, raising concerns that e-cigarette use could
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become the new gateway to conventional cigarettes and other tobacco product initiation as well
as further drug addiction.23 Recent cross-sectional studies have found that former smokers are
more prone to using e-cigarettes than never-smokers, and current smokers are much more prone
to using e-cigarettes than both never and former smokers.20-22 A recent US national trend
assessment showed that e-cigarette use has been exponentially increasing among smokers and
non-smokers alike over the past few years, with the use of e-cigarettes estimated to have reached
more than 30% among daily and non-daily smokers in 2013 reflecting an evolving dual use of
cigarettes and e-cigarettes. 24 Thus, e-cigarette dual use and gateway to other forms of tobacco
use are two major concerns that have been long discussed among tobacco control researchers and
have resulted in a concern that e-cigarettes could help renormalize tobacco use.25
E-cigarettes and Tobacco Control: The Debate over Harm Reduction and Smoking
Cessation
E-cigarettes are believed to be safer than conventional cigarettes. This belief is held by
many26-30 including physicians.31-33 However, e-cigarette vapors are not pure nicotine; they
contain a complex mixture of potentially lethal chemicals.34, 35 Thus, assessments of the abuse
potential and long-term adverse events are still needed,9 and the health implications are yet to be
understood.36 Whether e-cigarettes could be a safe substitute for regular cigarettes is not
known,37, 38 and pending any regulation by the US Food and Drug Administration (FDA), the
safety issues associated with the use of currently marketed e-cigarette products in the US is not
expected to be resolved anytime soon.29 E-cigarettes contain nicotine in varying levels.39 At
times there is no nicotine,29 and fewer carcinogens than are found in conventional cigarettes.40, 41
On the other hand, other harmful ingredients have been found in e-cigarettes such as diethylene
glycol which is a toxicant found in antifreeze.42, 43 Moreover, the main constituent of the e-liquid
3

(propylene glycol) has been rendered safe to use in some FDA-approved injectable drugs but has
never been tested for inhalation in human lungs. The long- and short-term effects of inhaling
such products remain unknown.44 Thus, the potential of e-cigarettes to be a viable harm
reduction strategy by minimizing tobacco use-related morbidity and mortality among those who
use them is not known and is difficult to project given the unresolved safety concerns.45
Nevertheless, there are researchers who support the use of e-cigarette for harm reduction,14, 45
and others who do not support e-cigarette use as a harm reduction strategy as this approach is
believed to be currently non-evidence based.46
E-cigarettes, since their emergence in the US market, have been heavily marketed as
smoking cessation aids.29 An abundance of websites contain testimonials from current and
former tobacco users as well as endorsements by physicians who, based on experiences with a
few patients, promote e-cigarettes as effective and safe cessation agents.2, 4, 47 Although ecigarettes are not currently regulated by the FDA, some cities in the US have banned use of ecigarettes in public places.48 Also, other countries have taken action to control the fast growing
market of e-cigarettes. The European parliament issued a ban on e-cigarette advertising that is
scheduled to go into effect in the 28 European union countries in 2016.49 Further, the United
Kingdom has banned nicotine liquid concentrations higher then 20mg/ml in an attempt to control
the nicotine yield.50
Recently, there have been a number of studies aiming at exploring their effectiveness as a
smoking cessation tool.37, 51-53 However, most of these studies lack a rigorous research design or
biochemical validation for nicotine abstinence, or they rely on self-reported data from online
surveys51 which could potentially include favorable biased responses from e-cigarettes
enthusiasts.54 For example, Polosa et al. (2011) followed 40 smokers who were unwilling to quit

4

but attempting to experiment with e-cigarettes as a method of tobacco reduction and possibly
cessation. They reported significant decreases in the amount of cigarettes smoked by study
participants. Bullen et al. (2010) conducted a randomized cross-over trial in New-Zealand among
40 adult dependent smokers. The e-cigarettes that were used in this study were found to alleviate
nicotine craving upon overnight abstinence.38 Until 2013, use of e-cigarettes did not correlate
with successful quit attempts.55 However, there is evidence that smokers try it in an attempt to
quit,52 and the first clinical trial published in September of 2014 suggested that e-cigarettes could
be as effective as nicotine patches in helping cigarette smokers quit.56 Finally, a more recent
cross-sectional study from England, without biochemical validation, surveyed smokers trying to
quit with e-cigarettes, approved cessation medications, or with no assistance. This study found
that there was a small, but statistically significant, continued abstinence among e-cigarette
users.57
Each of the aforementioned studies concluded that e-cigarettes might have a future in the
arena of smoking cessation, but acknowledged the need for more rigorously designed research.
Furthermore, most of these existing studies either did not report financial disclosure or reported
support by the manufacturers of these products.37, 38, 51, 52 A recent meta-analysis of these existing
studies supported e-cigarettes as a potentially effective smoking cessation aid.58 Nevertheless,
the available data regarding e-cigarettes efficacy in smoking cessation is not conclusive and thus,
e-cigarettes have not been endorsed by any professional health organization as an effective tool
for smoking cessation, including the American Heart Association,59 the American Association
for Cancer Research, the American Society of Clinical Oncology,60 or the United States
Department of Health and Human Services.61 Additionally, the current tobacco use cessation
guidelines state that the use of any tobacco product should be discontinued; quitting all forms of
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tobacco use is the only known method for decreased morbidity from tobacco.62 There is valid
concern that smokers would use other forms of tobacco in conjunction with e-cigarettes, creating
dual users or continue using e-cigarettes exclusively.4, 53 Thus, the prospects of e-cigarette use in
smoking cessation are still unresolved.
Physician Tobacco Use Counseling: A Current Perspective
Many tobacco users are now identified and offered cessation assistance during physician
office visits.63, 64 Tobacco use cessation discussions with physicians are considered an evidencebased brief intervention to help tobacco users quit.65, 66 In 1996, the US Public Health Service
first published evidence-based clinical practice guidelines for treating tobacco use and
dependence.62, 67 Since that time, recommendations for physicians have remained unchanged.62, 68
Physicians should ask patients about their tobacco use on every possible occasion as well as
counsel current tobacco users using a 5 As approach (ask about tobacco use, advise to quit,
assess willingness to make a quit attempt, assist in quit attempt, and arrange follow-up).62, 69, 70
If the patient is not ready to quit, recommendations are for the clinician to divert from the 5 A’s
approach after the “Assess” step, and instead use brief motivational counseling based on a 5 R’s
approach (i.e., relevance, risks, rewards, roadblocks, repetition).69 Primary care is an ideal venue
for the delivery of such interventions,62 as periodic health exams are regarded as a time for
preventive health-related counseling by physicians on tobacco use among other issues.71 A
physician’s visit serves as a trigger for tobacco use quit attempts.72 Further, tobacco users
perceive a physician's advice to quit as a strong motivator for a cessation attempt.73-75 A
Cochrane review concluded that brief advice by physicians versus no advice significantly
increases quit rates,76 and this brief advice is deemed as the standard of care for tobacco use
cessation counselling.62
6

The emergence of e-cigarettes is believed to be interacting with physician cessation
counseling behavior.77 There is no identified published literature detailing physicians’ counseling
practices regarding e-cigarettes either inside or outside the US; however, there is anecdotal
evidence that US physicians recommend e-cigarettes for tobacco use cessation based on their
personal experiences and information obtained from their colleagues.78 Such anecdotal
information is beginning to be confirmed via large scale research efforts. For example, a recent
survey of practicing physicians in North Carolina found that discussing e-cigarettes with patients
was not an uncommon practice albeit being patient initiated.32 Another online survey yielded
similar conclusions using a quota sample of physicians practicing in different specialties.33
Discussing smoking cessation recommendations with the advent of e-cigarettes, in light of
inconclusive evidence regarding their safety and efficacy in cessation,59-61 is likely to cause
additional complexities for clinicians,77 particularly among primary care physicians (PCPs) who
currently deliver the vast majority of office-based physician tobacco cessation counseling63, 64, 79
and are at the forefront of the US health care system. Despite guideline recommendations to do
so,62 even before the emergence of e-cigarettes, clinicians counseling current tobacco users have
not always recommended FDA-approved cessation pharmacotherapy.80 Some physicians have
negative attitudes toward providing pharmacotherapy for cessation,81 and these perceptions
greatly moderate prescribing behavior.82 A study by Bhatia et al (2006) found that there are four
main drivers of physician pharmacotherapy choice: product characteristics; promotional
activities; patient treatment history and co-morbidity; and price-related issues.83 E-cigarettes are
rapidly evolving with regard to the product characteristics with varying price categories and
there is limited knowledge about their safety and efficacy for smoking cessation,29 but PCPs are
likely lacking information about these aforementioned topics.31, 32 Additionally, promotional
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activities (a third driver) are abundant and currently unregulated, centering on the message that
e-cigarettes are a safe alternative and can help in quitting.3, 47 Such activities could be affecting
PCPs beliefs and knowledge regarding e-cigarettes as some of them reported that they gather
their information from their patients, the lay-press, and e-cigarette advertisements.31 In summary,
e-cigarettes represent a new product that could be challenging the use of FDA-approved
pharmacotherapy cessation aids or more broadly altering the dynamics of smoking cessation
counselling. E-cigarettes are likely a “hot topic” for discussion during physician office visits and
their emergence could be forcing physicians to give an opinion on them once a tobacco use
cessation discussion takes place, despite the lack of empirical evidence regarding the benefit of
these products in smoking cessation.
Current Knowledge about Physicians’ E-cigarettes Recommendations
Despite the ever growing access among the US public to medical information, the
preference of the majority (70%) continues to be obtaining health information from their
physicians. 84 Moreover, physicians remain the most trusted source of health information.84, 85 In
the absence of a clear set of recommendations from clinical practice organizations or regulatory
actions from the FDA,86 PCPs likely face a challenge when addressing patient inquiries
regarding e-cigarettes. Understanding the burden on PCPs in providing tobacco counsellingrelated information is of critical importance as there are an abundance of opposing views and
conflicting evidence regarding e-cigarette safety and benefits with no conclusive guidance in
clinical practice.37, 38 For example, the American Heart Association issued its first set of policy
recommendations regarding e-cigarettes including counselling recommendations to physicians
using the existing body of literature at the time.59 They recommended that physicians screen for
e-cigarette use. However, they acknowledged that there was no evidence to support e-cigarette
8

use or recommendation for cessation. On the other hand, there was also no evidence to support
deterring patients who had previously tried other cessation aids unsuccessfully and were
interested in using e-cigarettes.59
Existing surveys of physician attitudes and perceptions in the US confirm that ecigarettes are being discussed, and that physician opinions are being solicited by patients,
especially among primary care specialties.31, 32 Four out of five physicians reported being asked
about e-cigarettes by their patients who used tobacco in one study and nearly half of physicians
who believed that e-cigarettes may assist in cessation already had recommended them to their
patients.32 Physicians who were younger, believed that e-cigarettes lowered the risk of cancer,
had been asked more often about e-cigarettes by their patients and had a process in place to
document tobacco treatment counseling were more likely to report making such a
recommendation. These results were consistent with another survey that found that many
physicians are being asked about e-cigarettes and are recommending e-cigarette use to their
patients.33 However, the full range of factors which contribute to physicians attitudes,
perceptions and decisions to recommend e-cigarettes remains largely unknown.31, 32 Without
knowledge of the factors that are likely to impact e-cigarette recommendations in clinical
practice, up-to-date program planning for addressing the current challenges in tobacco use
counselling in physicians’ offices remains at a standstill.
The Aims of My Research
The overarching objective of my dissertation research was to understand the patient,
physician and other influences pertaining to the adoption of e-cigarettes into a primary care
physician’s tobacco cessation counseling. Since approximately half of the physician office visits
in the US are with PCPs,79 and tobacco use is screened in approximately 75% of the visits in
9

primary care,64 I targeted PCPs to evaluate physicians’ behavior. My primary research question
was centered on understanding how e-cigarettes are being incorporated into primary care tobacco
use cessation counseling. I also identified the underlying salient factors that contributed to PCP
endorsement of e-cigarettes when engaging in tobacco use cessation counseling. My exploration
of how physicians and patients discuss e-cigarettes in clinical practice, and how these discussions
affect physicians’ recommendations of their use, requires an in-depth understanding of
physicians’ perceptions of e-cigarettes. My research was guided by the Theory of Reasoned
Action (TRA).87, 88 Because the environment surrounding cessation discussions is also important,
I augmented the TRA with the concept of patient interest for a specific treatment option that is
highlighted by the Model of Clinical Decision Making (MCDM). TRA suggests that attitudes
and subjective norms contribute to physicians’ intentions and subsequent decisions to
recommend e-cigarettes to their patients once the tobacco use cessation discussion takes place.87,
89, 90

MCDM suggests the patient’s interest in receiving a specific treatment becomes more

important for physicians if they are addressing a chronic problem that is not immediately life
threatening to the patient.91 All these domains interrelate which prompted me to combine them in
a TRA-informed conceptual model. This resulting combined conceptual model guided my
research as depicted in Figure 1.

Patient Interest

Figure 1: Model of the Factors Influencing Physicians’ Decision to Endorse E-cigarettes
10

My research study was carried out in two phases. Phase-1 used qualitative methods to
discover the factors associated with PCP recommendation of e-cigarettes for tobacco use
cessation. This formative research included an elicitation procedure to identify relevant
behavioral outcomes and referents. To do so, I used semi-structured interviews in which PCPs
were asked to provide three types of information: 1) Positive or negative feelings about
recommending e-cigarettes as a tobacco use cessation aid (experiential attitude or affect), 2)
Positive or negative attributes or outcomes of recommending e-cigarettes as a tobacco use
cessation aid (behavioral beliefs), and 3) Individuals or groups to whom they might listen who
are in favor of or opposed to the recommendation of e-cigarettes as a tobacco use cessation aid
(normative referents). Phase-2 used quantitative methods to estimate, among others variables,
the prevalence of e-cigarette recommendation for tobacco use cessation and its related factors. In
so doing, my research was designed to address the following aims:
Aim 1: Uncover the factors associated with PCPs’ decisions to recommend e-cigarettes to
their patients;
Aim 2: Estimate the prevalence of PCPs who recommend e-cigarettes to their patients;
Aim 3: Estimate the influence of factors identified in Aim 1 on PCPs’ decisions to
recommend e-cigarettes to their patients;
Aim 4: Evaluate the conceptual model which demonstrates the factors contributing to
PCPs’ decisions to recommend e-cigarettes to their patients.

11

Chapter 2: Primary Care Physicians’ Beliefs and Practices Regarding Ecigarette Use by Patients Who Smoke: A Qualitative Assessment
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ABSTRACT
Background: There is growing evidence that e-cigarettes are being discussed and recommended
during physician office visits. Factors underlying these conversations and physician
recommendations regarding e-cigarette use remain unknown. Objective: To explore primary
care physicians’ (PCPs’) beliefs and practices about e-cigarettes. Design: Cross-sectional, semistructured interviews with PCPs in 2014 were conducted and audio-recorded. Study Population:
Participants were 15 general internal medicine and family practice physicians practicing in two
settings in Virginia, USA. Coding and Analysis: Interview recordings were transcribed, and the
content analyzed using the constant comparative method to identify key themes regarding PCPs’
reported current practices and beliefs. Results: Five themes were identified: PCPs report 1)
noncombustible tobacco products (such as e-cigarettes) receive little proactive screening
attention within existing clinic processes, 2) patients commonly initiate e-cigarette discussions,
and seek physician guidance regarding e-cigarette use, 3) a lack of knowledge regarding the
potential harms and benefits of e-cigarettes, 4) believing e-cigarettes are a safer alternative to
smoking combustible tobacco products, and 5) abandoning concerns regarding the potential
harms of e-cigarettes in the context of highly addicted patients and those with extensive
comorbidities. Limitations: Physician practices and beliefs are reported from two primary care
practices and ability to generalize study findings may be limited. Conclusions: Despite
acknowledging limited knowledge regarding e-cigarettes, findings suggest that some primary
care physicians are currently recommending e-cigarettes to their patients for smoking cessation
and relative harm reduction, often personalizing recommendation based on the patient’s
perceived level of addiction and current health status. Physicians need to be informed about the
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evolving evidence regarding the risks and benefits of e-cigarettes to be able to competently steer
e-cigarettes-related discussions with their patients.
Abbreviations
US

United States

PCP

Primary Care Physician

FDA

Food and Drug Administration

ACORN

Ambulatory Care Outcomes Research Network
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INTRODUCTION
A wide range of new and emerging tobacco products are thriving in the United States
(US) despite limited knowledge of their health implications.2, 29 One such product, the ecigarette, is marketed as a cessation aid, harm reduction strategy or both.2, 4 As evidenced by a
number of recent studies, experimentation, use, and promotion of e-cigarettes have been growing
exponentially over the past few years.6, 24, 29, 92 Despite this growth, how e-cigarettes are
perceived by physicians is not fully understood.31, 32
National clinical organizations such as the American Heart Association,59 American
Association for Cancer Research and the American Society of Clinical Oncology60 have recently
issued policy statements regarding e-cigarettes, advocating that physicians screen for the use of
e-cigarettes, but continue to recommend only Food and Drug Administration (FDA)-approved
pharmacotherapies for cessation. Most recently, the US Preventive Services Task Force
continued to support the use of only FDA-approved pharmacotherapies for cessation, and not ecigarettes, citing a lack of sufficient evidence surrounding e-cigarette potential to aid with
smoking cessation.61
With the absence of either a comprehensive set of recommendations from professional
organizations or regulatory actions from the FDA,86 physicians are likely to rely on their own
perceptions when discussing e-cigarette use with their patients who smoke. Current evidence
suggests that e-cigarettes are being discussed in physicians’ offices in multiple settings.31-33, 77
Yet, to our knowledge, there are only two examples of published reports that include US-based
primary care physicians (PCPs).32, 33 Both reports rely solely on data from physician surveys, and
found that patients actively solicit their PCP’s opinions regarding e-cigarettes. Despite these
studies, how PCPs approach e-cigarette discussions, and the full range of factors that contribute
15

to their beliefs, perceptions and decisions to recommend e-cigarettes remain largely unknown.31,
32

The purpose of this study is to describe PCPs’ current tobacco use screening behavior as
it pertains to e-cigarettes, identify PCPs’ current approaches to tobacco use cessation counseling
as well as to explore their beliefs and practices about e-cigarettes, and to understand the context
in which they might recommend e-cigarette use to their patients who smoke.

METHODS
Study Participants
Participants were family and general internal medicine physicians employed by a large
university health system in Richmond, Virginia, supplemented by an additional sample of family
medicine physicians practicing in the Virginia Ambulatory Care Outcomes Research Network
(ACORN) located in northern Virginia. ACORN is a network of family medicine, internal
medicine, paediatrics, nursing or other specialties with a mission to improve health and
transform care delivery through primary care research and implementation.93 We purposefully
sampled from different practice settings to ensure that sampled physicians treated heterogeneous
patient populations across a diversity of settings and geographic areas in Virginia. In April of
2014, we contacted all family and general internal medicine physicians working at the university
health system (N=46) via e-mail to invite them to participate in the study. In July 2014, we
invited another (n=40) family medicine physicians practicing in two ACORN clinics. To be
eligible for participation, physicians had to report providing outpatient primary care to adult
patients and discussing tobacco use with at least one of their patients within the past 30 days.
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Participants did not receive any compensation for participation. All aspects of the study were
approved by the Institutional Review Board of the Virginia Commonwealth University.

Data collection
After providing written informed consent (Appendix 1), demographic and practice
information (i.e. age, gender, race/ethnicity, primary speciality, weekly patient volume and year
of training completion) was collected from each participant. Each PCP then participated in an indepth, semi-structured interview. The interview guide was designed to elicit a) current tobacco
use screening and counselling practices, b) perceptions of and beliefs regarding e-cigarettes and
c) their screening and counselling practices surrounding e-cigarettes. For the current analyses we
focused on responses to nine questions (See Figure 2: Text Box). All interviews were conducted
in person by the study PI (O.S.) between April and August, 2014 at the PCPs’ offices. Interviews
were audio-recorded, and ranged between 23 and 55 minutes. Prior to analysis all interviews
were transcribed verbatim.
Coding and Analytic Methods
Prior to coding, names and other identifying information were removed from transcripts.
Transcripts of audio-recorded interviews were analyzed using the constant comparative method
proposed by Glaser.94 The research team (O.S., R.B., J.E.L) conducted bi-weekly meetings
during which themes were identified and discussed. A consensus process was used to achieve
agreement on the inclusion of themes. Initially, as the methodology requires, a first set of
transcripts (n=5) was analyzed. Once an exhaustive analysis of this original data set was
complete, further sub-samples of transcripts were analyzed at a time until no additional themes
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were identified. The themes which emerged from these data were compared with those from the
original data set and if necessary, new thematic categories were defined. This process continued
until no new themes emerged. No further interviews were needed to be conducted after the 15th
interview. The emerging themes were intended to be descriptive of PCPs’ behaviors during
tobacco use cessation counseling with their patients who smoke and their beliefs regarding ecigarettes. This iterative process resulted in further refinement of the themes: reported themes
were agreed upon by the three authors.

1. How do you typically ask your patients to find about their tobacco use
status?
2. How do you go about counselling patients who are current tobacco users?
3. Have you ever asked any of your patients about their e-cigarette use?
If yes, “How did you go about doing that?”
4. Have any of your patients ever asked you about e-cigarettes?
If yes, "Can you estimate how often over the past year?” AND
“Can you tell me a typical question patients asked?”
5. Do you know if any of your patients use e-cigarettes?
If yes, " What are your thoughts about that?
6. Did you recommend e-cigarettes to any of your patients?
If yes continue probing Was there something specific about the
patient that led you to recommend/NOT recommend it? What was it
about the patient? Something they said?
7. What are your thoughts regarding e-cigarettes and other modes of tobacco
use? > How do you think e-cigarettes compare to other tobacco use
available?
8. What are your thoughts regarding e-cigarettes and smoking cessation? >
How do you think e-cigarettes compare to other cessation aids available?
9. Are there specific patients that you might be more or less likely to
recommend e-cigarettes to? >Give me an example of patient you are more
likely/least likely to recommend e-cigarettes for.
Figure 2: (Text Box) Semi-structured Interview Questions with Main Probes Used
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RESULTS
Study Population
Fifteen PCPs, seven from the university health system and eight from ACORN consented
to participate in the study. Eleven participants were family medicine physicians and four were
general internal medicine physicians. The mean age of participants was 43.1 years (SD=+10.3)
and on average they had been practicing for 15.4 years (SD=+10.6). PCPs were evenly
distributed by gender (i.e., 53% male and 47% female), and were predominantly white (60%) or
Asian (20%). The average patient volume was 63.2 patients per week (SD=+31.9).
Themes
Thirteen PCPs reported discussing e-cigarettes with their patients; of those, six reported
having previously recommended e-cigarette use to at least one of their patients. Five overarching
themes emerged from the qualitative analysis: 1) PCPs acknowledge that noncombustible
tobacco products (such as e-cigarettes) receive little proactive screening attention within existing
clinic processes, 2) PCPs report that patients commonly initiate e-cigarette discussions, and seek
physician guidance regarding e-cigarette use, 3) PCPs express a lack of knowledge regarding the
potential harms and benefits of e-cigarettes, 4) PCPs believe that e-cigarettes are a safer
alternative to smoking combustible tobacco products, and 5) PCPs’ concerns regarding the
potential harms of e-cigarettes are abandoned in highly addicted patients and those with
extensive comorbidities. Each theme is described below with illustrative interpolations from
transcript data.
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Theme 1: PCPs acknowledge that noncombustible tobacco products (such as e-cigarettes)
receive little proactive screening attention within existing clinic processes.
While participating PCPs reported established processes to screen for combustible
tobacco products, none reported a similar process for new and emerging tobacco products,
including e-cigarettes. There were multiple office-based processes reported to screen for patient
smoking status. Generally, these processes started with nursing staff screening for use and
documenting results in the electronic health record for later PCP follow up during office
discussions. Most PCPs indicated that they ask about their patients’ smoking status as part of
their routine screening process, but do so without probing into smokeless tobacco products –
“Typically we’ll ask as part of the routine
screening, but I will admit that for most routine
visits, I generally don’t probe into smokeless
tobacco products.” [PCP A]
PCPs also reported particularly not screening for e-cigarette use –
“I don’t ask specifically about smokeless tobacco,
chewable tobacco, e-cigarettes. It’s generally just
‘Do you smoke?’ or ‘Were you a smoker in the
past?’ and then ‘How much, over what period of
time?” [PCP B]
Some of the PCPs expressed having less concern about noncombustible tobacco products –
“Usually lesser for some reason that I am worried
about chewing tobacco or snuff. I don’t ever
specifically ask about e-cigarettes. So, 90% of
patients I ask the question “do you smoke?” and
leave it at that.” [PCP C]
However, a few PCPs reported probing for different tobacco products–
“I ask them if they’re smoking, but then generally
I’ll also get down to then ‘Are you chewing? Are
you using the dip?” [PCP D],
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and with exception of one physician, none of those PCPs reported ever probing for e-cigarette
use.
Theme 2: PCPs report that patients commonly initiate e-cigarette discussions, and seek
physician guidance regarding e-cigarette use.
PCPs consistently expressed that it is patients who usually initiate e-cigarette
discussions–
“E-cigarettes have definitely been coming up in the last
six months. I would say maybe the last year, but in the
last six months more and more patients are mentioning
it as an alternative or something they are looking to
instead of traditional smoking.” [PCP E]
Furthermore, patients’ expression of interest was expressed to be a primary reason for a PCP to
recommend them for smoking cessation–
“I believe in patient-centered care, and I think that
changing your health behaviors is really hard. So
whatever my patient thinks is going to help them with
quitting smoking, I would support, and that would
include e-cigarettes, if they wanted to do that.” [PCP F]
The salience of patients’ interest in trying e-cigarettes was common across all PCPs, both those
who recommended e-cigarettes to their patients–
“If they bring it up and they have a motivation I’m
usually very encouraging.” [PCP A],
and those who had not previously recommend e-cigarette use to their patients prior to the study–
“Somebody who comes to me and specifically says,
I am thinking of switching then the patient
preference would be a factor in this case.” [PCP G]

21

For some PCPs, discussion of e-cigarettes was reported as relatively frequently
“E-cigarettes come up all the time now, sometimes
our patients have started doing them on their own,
or they have friends who are doing them and they
ask about them, so they come up pretty routinely
now.” [PCP D]
Theme 3: PCPs express a lack of knowledge regarding the potential harms and benefits of
e-cigarettes.
Regardless of whether a PCP had recommended e-cigarettes, all expressed a lack of
knowledge about e-cigarette safety and their efficacy as a smoking cessation aid. One PCP who
had not recommended e-cigarette use said–
“The safety is not listed there and you don’t know
what they’re actually putting into it. They may not
be labeling it correctly and that you may be putting
other carcinogens in yourself and maybe you’re not
getting as much smoke, but there are other things
that you’re getting.” [PCP H]
On the other hand, a PCP who had previously recommended e-cigarettes said–
“I wouldn’t say it’s safe, because nicotine can make
your heart rate go up, and vaso-constrict, if
somebody takes the e-cig and takes 30 or 40 puffs in
a row, that’s probably not good for their coronary
vasculature. So I guess in certain ways you could
have more harm to the heart than a regular
cigarette, perhaps, in certain situations.” [PCP I]
With regards to the efficacy of e-cigarettes for smoking cessation, one PCP commented on the
need for scientific evidence and commented that such evidence regarding e-cigarettes is lagging
behind that for other established FDA-approved pharmacotherapies by saying–
“I want to see a research study that shows that
that’s helped. There are great research studies with
Chantix, with Wellbutrin, with patches and with
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doctors’ counseling. So we know that patients on
average, 7% of patients quit smoking just on their
own volition. If you start adding things like Chantix
and Wellbutrin, you can get it up to 15 to 23%. I
want to see a study like that, that randomizes people
to e-cigarettes versus Chantix, versus patches,
versus doctors just telling people to quit smoking,
and when I see that, then I’ll say it’s an effective
means of helping people quit, but there’s no data on
that. It has to be studied.” [PCP F]
Moreover, PCPs expressed not only that they have a lack of knowledge but that there is not yet
enough information regarding e-cigarettes and that it is not easy to find such information by
saying–
“I tell them is that we don’t have a lot of data on
the e-cigarettes because they’re not FDA-regulated
yet and so individual safety data is complicated.
The only stuff I’ve been able to find is from the
manufacturers and some Australian stuff, and of
course that’s all done by the people that sell the
cigarettes. So, I just give them all the information
that we have, which is not much, and if they want to
try it, I say I don’t really have a strong objection to
you doing that.” [PCP D]
Theme 4: PCPs believe that e-cigarette use is a safer alternative to other tobacco products.
All PCPs expressed concerns about the potential harms of e-cigarette use. However, most
PCPs expressed that e-cigarette use is likely safer than the use of traditional tobacco products –
“I think, in general taken as a whole, they’re safer than smoking, chewing
tobacco, pipes, cigars probably.” [PCP I]
Most of the PCPs used cigarette smoking as the benchmark for establishing a comparison for ecigarettes’ safety as a nicotine delivery product, one PCP elaborated on this by saying–
“What I want to know is that they are safer than
cigarettes, because it’s that risk-benefit thing. So if
someone’s already smoking cigarettes, if I can’t get
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to perfect, which is nothing, and there are some risks
associated with the inhaled nicotine, but it’s less
than the inhaled cigarettes, I’ll take the e-cigarettes.
I can’t imagine it’s not safer than the actual
cigarettes, because cigarettes are just known to be
bad for you in so many ways.” [PCP D]
In addition to that, PCPs acknowledged that their perception of e-cigarettes
being safer than other combustible tobacco products, is a factor in their
recommendation when coupled with the interest of their patient to try ecigarettes, one PCP explicitly explained that by saying–
“There is a perception- kind of automatic responsethat it must be safer. Because it is not smoking, so
it’s got to be better than smoking. And what I have
tried to tell patients is that we don’t actually know
that to be the case. We don’t know anything about ecigarettes in terms of safety, we don’t know if they
are harmful, we don’t know if they are not harmful,
we do know smoking is harmful, so I often times let
patients come to a decision that they are more
comfortable with” [PCP E]
However, the same PCP further shared more skepticism about the absolute
safety with e-cigarettes, while still acknowledging the likely relatively
safety benefit of e-cigarettes compared to traditional cigarettes by saying–
“I am very, very skeptical about a lot of it, I think
it’s being advertised as a safer, healthier
alternative, I don’t think it is true and if it is, it
won’t be safe, it will be safer and it still won’t be
something that is very good for people. The vapor
from the e-cigarettes has some of the chemicals that
you find in tobacco smoke, and the liquid itself of ecigarettes is incredibly dangerous” [PCP E]
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Theme 5: PCPs’ concerns regarding the potential harms of e-cigarettes are abandoned in
highly addicted patients and those with extensive comorbidities.
PCPs reported recommending e-cigarettes to heavy smokers or to patients with existing
co-morbidities–
“ The people who are smoking like a pack a day
and really chimneys, I’m like you want anything
that you can do that’s an action that gets in the
right direction. So I usually am pretty encouraging
of it in that setting.” [PCP K]
In other instances, PCPs were more inclined to recommend e-cigarettes for heavy long-term
smokers who have previously tried quitting and failed with conventional cessation medications
and who may be addicted to the social habit of smoking. For example one PCP said–
“If somebody said to me, ‘Doc, I’ve already tried
the gum. I’ve tried the patches. It didn’t work for
me, and I’m not really interested in taking these
antidepressant medicines that you’ve talked about
with the craving. I think I’m just so hooked on the
physical act of smoking that I think the e-cigarettes
are going to be a better way for me to bridge to
using,’ so I would probably recommend ecigarettes.” [PCP J]
Similarly, a PCP acknowledged that recommending e-cigarettes for cessation could be a good
option for a cessation attempt with patients with smoking related co-morbidities–
“When I think of any therapy that I might
recommend to someone without really feeling like
it’s super well-established or that I really understand
all the risks and benefits, it’s like people who stand
the most to gain by using it, so people who are like
long-term smokers or who I know will do really
poorly with some of the medications or other options
that are out there, people who I just think
behaviorally would be more amenable to something
like that, I guess those would be the people that I
would think more of using it” [PCP K].
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DISCUSSION
Five themes emerged in our current study and the information within these themes
suggests that despite routine screening for conventional tobacco use, screening for e-cigarette use
seems not to be yet established in primary care. However, smokers and their physicians
frequently discuss e-cigarettes during primary care office visits. Although PCPs report not
typically initiating these e-cigarette discussions, citing a general lack of knowledge regarding the
potential benefits and harms of e-cigarettes, they nonetheless perceive e-cigarettes to be a safer
alternative to other tobacco products, particularly combustible cigarettes. Furthermore, some
PCPs acknowledge recommending e-cigarettes to at least some of their patients who smoke.
They tend to be more likely to recommend e-cigarettes for harm reduction and smoking cessation
to certain patient profiles including those thought to be highly addicted to smoking, whose
current health status is perceived as warranting immediate action, and who have had a prior
failed quit attempt using FDA-approved pharmacotherapies. Moreover, patients’ interest in
trying e-cigarettes appeared to be a particularly salient facilitator in PCPs’ decisions to
recommend e-cigarette use.
Faced with little empirical evidence,2, 60 difficulty finding relevant risk/benefit
information, and a void in professional guidelines,62 PCPs seem to be developing their own
approaches to incorporating e-cigarette use into their reportedly increasing patient inquires about
e-cigarette use ,31-33 and tobacco use related counseling. Prior research31-33 has shown that PCPs
in general believe that e-cigarettes are safer than traditional cigarettes. While PCPs in our study
share that belief, they were less consistent in acknowledging the efficacy of e-cigarettes as a
smoking cessation aid. Nonetheless, most PCPs in our sample reported being more willing to
recommend the use of e-cigarettes to patients they perceived as highly addicted or those with
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extensive smoking-related comorbidities than to other smokers. Because such recommendations
are being made despite PCPs’ overall skepticism regarding the efficacy of e-cigarettes as a
smoking cessation aid, this suggests that PCPs’ willingness to recommend e-cigarettes may be
driven by their belief in e-cigarettes’ capacity for relative harm reduction.
Our results indicate that, in spite of PCPs uncertainty about e-cigarettes, they are
recommending them to patients and these recommendations are supported by patient interest in
trying e-cigarettes. Thus PCPs in our study seemed to adopt a patient centered approach when
communicating with their patients about e-cigarettes.95 When patients raised the topic of ecigarettes, PCPs reported explaining the limited information they know about e-cigs, and actively
supporting a patient’s decision to try them. In fact, it is plausible to suggest that patients are a
likely source of information for PCPs about e-cigarettes and may be indirectly driving PCPs’ ecigarette beliefs and practices. Yet, it is also likely that patient and physician e-cigarette
knowledge is directly influenced by industry marketing and advertising as well as lay press
publications regarding the evolving market of e-cigarettes.31, 96 This coupling of indirect and
direct influence on PCPs is reminiscent of the influence of historical conventional tobacco
advertising, but is differentiated by the aid of the global spread afforded by social media.97, 98
Despite recommendations to screen and counsel patients for e-cigarette use,59, 60
expecting most PCPs to proactively do this is likely unrealistic given the void in relevant
evidence to help PCPs steer a conversation once patients’ use of, or interest in using, e-cigarettes
is established. Instead, it appears that increasingly frequent office-based interactions regarding ecigarettes are causing PCPs to develop non-evidence based opinions and then use those opinions
in their routine tobacco use cessation counseling to address their patients’ inquiries about ecigarettes. Despite the FDA and many researchers racing to fill these evidence voids, the reality
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is that it will take many years before we understand the full range of public health benefits and
risks associated with e-cigarettes,29, 61 and thus the health and other implications of current PCP
beliefs and practices regarding e-cigarettes.
Limitations
The results of our study should be interpreted in the context of several limitations. First,
study data were collected between May and August of 2014, and given the rapidly evolving ecigarette market the applicability of findings to today’s practices should be interpreted with
caution. Second, PCPs interviewed were limited to those practicing within two Virginia settings
and included only a small number of the potentially eligible physician subjects within these
settings. As such, care should be taken when generalizing findings to other settings and
providers. Nevertheless, to our knowledge this is the first study to use qualitative research
methods to assess comprehensively PCPs’ beliefs and practices regarding e-cigarettes and
articulates underlying reasons behind PCPs’ recommendations of e-cigarettes.
CONCLUSION
In conclusion, PCPs expressed a lack of information about e-cigarette safety and efficacy
along with skepticism about the role of e-cigarettes in tobacco control in general and in smoking
cessation in particular. However, once a patient initiates a discussion with them, PCPs seem to be
endorsing patients’ interest in using e-cigarettes, as well as recommending e-cigarettes to
particular types of patients who smoke for both smoking cessation and as a harm reduction
strategy. Such findings serve to illustrate the importance of generating and rapidly disseminating
evidence regarding e-cigarette safety and efficacy for smoking cessation to US physicians.
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Without such effort, PCPs will continue to devise their own beliefs and practices regarding ecigarettes that are likely to be difficult to change once established.99
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Chapter 3: Physicians’ Knowledge, Beliefs and Practices Regarding Ecigarettes: Results from a national survey of US primary care physicians
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ABSTRACT
Background: E-cigarette use is exponentially increasing in the United States despite limited
knowledge about their potential harms or benefits. Objective: To understand the extent to which
PCPs report e-cigarette discussions and recommendations as well as their knowledge and beliefs
regarding e-cigarettes and how these influence their propensity to recommend e-cigarettes to
their adult patients who smoke. Methods: We used a modified Dillman approach to administer a
mailed survey to a national random sample (N=1430) of office-based primary care physicians
(PCPs) between February and May, 2015. Survey content was informed by existing literature
and qualitative research. Chi-square tests and t-tests were used for bivariate analysis, as
appropriate to compare PCPs who recommend and do not recommend e-cigarettes. M-Plus with
full information likelihood estimation was used to identify factors associate with PCPs who
reported previously recommending e-cigarettes. Results: 328 PCPs returned the survey for a
24% response rate. 82.7% of eligible PCPs (n=220) reported previously discussing e-cigarettes
with their patients and 57.8% (n=155) reported previously recommending e-cigarettes to their
patients who smoke. The majority reported recommending them for smoking cessation and harm
reduction (71.6%, n=111), 19.2% for smoking cessation only, and 9.6% for harm reduction only.
PCPs’ knowledge regarding e-cigarettes, particularly potential harms, was low, but beliefs
regarding e-cigarettes ability to help in quitting smoking and to help limit secondhand smoker
exposure to others, decreasing cancer risk and the perception that e-cigarettes offer a relative
harm reduction tool compared to other tobacco products was high. Patients’ interest in using ecigarettes (odds ratio=1.31, 1.09-1.58) and the PCP having favorable beliefs regarding ecigarettes ability to help in quitting smoking (odds ratio=1.80, 1.45-2.24), to limit secondhand
smoke exposure for others (odds ratio=1.45, 1.15-1.83), to reduce harm compared to other
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tobacco (odds ratio=1.11, 1.05-1.16), and deter patients from using conventional cessation
medications (odds ratio=0.78, 0.64-0.95) were associated with PCPs’ reports of previously
recommending e-cigs to their patients who smoke Limitations: Having a low response rate and
potential for response bias limit ability to generalize beyond sample. Conclusion: Results
illustrate an opportunity to improve PCPs’ e-cigarette-related knowledge while their practice is
still developing. The impact of improving PCPs’ knowledge on their recommendations is
unknown. However, once their practice is established it is difficult to change.
Abbreviations
US

United States

PCP

Primary Care Physician

AMA

American Medical Association

GIM

General Internal Medicine

FP

Family Practice

GP

General Practice

FDA

United States Food and Drug Administration
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INTRODUCTION
E-cigarette use has been increasing exponentially in the United States (U.S.) among
smokers and non-smokers alike.20, 22, 24, 29, 92, 98 Although, e-cigarettes have been marketed as
both a harm reduction strategy and as a smoking cessation aid,22, 29, 92, 98 evidence regarding ecigarette safety and their efficacy as a smoking cessation aid is still emerging.22, 32, 61 E-cigarette
use has been linked to a steep increase in calls to poison centers, mostly among children (ages 05), in the US between 2012 to 2014 to report side effects due to inhalation or skin contact like
nausea or vomiting.100 As of yet, e-cigarettes has not been linked directly to any serious adverse
events;101 however, the liquid nicotine used in e-cigarettes can contain some of the toxicants and
carcinogens found in traditional cigarettes,40, 41, 102-104 and studies suggest that e-cigarette use can
cause acute adverse pulmonary effects.105, 106 Moreover, the amount of nicotine delivered by ecigarettes varies greatly from no nicotine to levels higher than that found in conventional
cigarettes.12, 13, 35 Furthermore, while some early studies point to the potential for e-cigarettes to
serve as an effective smoking cessation aid, 37, 38, 51, 52, 107 many such studies have been industry
sponsored and/or criticized for their methodological limitations.37, 38, 52
E-cigarette production and marketing are not currently regulated by the U.S. Food and
Drug Administration (FDA),36, 108 and the US Preventive Health Services Task Force recently
concluded that there was insufficient evidence to recommend their use as a smoking cessation
aid.61 National clinical organizations such as the American Heart Association,59 the American
Association for Cancer Research, and the American Society of Clinical Oncology60 have issued
position statements regarding e-cigarettes. These organizations generally have advocated that
clinicians screen for the use of e-cigarettes, but offer little guidance once e-cigarette use is
identified,59-61 advising only that physicians share the limited evidence base regarding their
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safety and efficacy while continuing to recommend FDA-approved pharmacotherapies for
smoking cessation.59-61
Given the limited guidance from national clinical organizations and the general lack of
conclusive evidence regarding either the full health implications of e-cigarettes or their efficacy
in smoking cessation,2, 29, 31 physicians may be relying on their patients, the e-cigarette industry
and information in the lay press as sources of e-cigarette-related information.31 Recent finding
suggest that patients are seeking advice from their physicians regarding e-cigarette use and that
some physicians are recommending e-cigarettes to their patients who smoke.8, 30, 31 Physicians
and patients alike, seem to believe that e-cigarettes can help with quitting,2, 8, 30-32 and are less
harmful in comparison to conventional cigarettes.17, 31-33, 92 Our own qualitative study found that
despite acknowledging limited evidence regarding the benefits and risks associated with ecigarettes, some primary care physicians (PCPs) recommend e-cigarettes to their patients who
smoke for both smoking cessation and harm reduction purposes.109 Furthermore, we found that a
PCP’s propensity to recommend e-cigarettes to a given patient seemed to be influenced by that
patient’s interest in trying e-cigarettes.
Despite insights from such studies, it remains uncertain how PCPs, who currently deliver
the vast majority of office-based physician tobacco use cessation counseling,63, 64, 79 are
incorporating e-cigarettes into their counseling practices and what factors might be influencing
this incorporation. To address this knowledge gap, we surveyed PCPs nationwide to understand
the extent to which they report e-cigarette discussions and recommendations as well as their
knowledge and beliefs regarding e-cigarettes and how these influence their propensity to
recommend e-cigarettes to their adult patients who smoke.
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METHODS
Sample Selection
Using the American Medical Association’s (AMA’s) Masterfile, we identified a sample
of General Internal Medicine (GIM), Family Practice (FP) or General Practice (GP) physicians
aged 75 years or younger actively delivering office-based care. We contacted a random sample
of N=1,430 PCPs supplied by an authorized vendor of the AMA’s 2015 Masterfile (Medical
Marketing Service, Schaumburg, IL; 2015).
Survey Development and Administration
The survey included items adapted from validated instruments of clinicians’ tobacco use
cessation counseling beliefs and practices,80, 110 and those specific to e-cigarette beliefs and
practices developed from results of our qualitative research.109 It also included e-cigarette-related
knowledge items developed in consultation with a leading expert in e-cigarette toxicity and
regulatory policy. Once developed, the survey was refined in response to comments from five
experts in psychometrics and patient-provider communication. The instrument also was pretested
for clarity and ease of understanding via semi-structured cognitive interviews with a convenience
sample of 10 PCPs practicing in an academic medical center; those PCPs provided an informed
consent for participation and received no compensation (Appendix 2). The final 32-item
questionnaire took approximately 15-20 minutes to complete, and was administered via the US
postal service using a Dillman process111 between February and May 2015 (Appendix 3). All
correspondence, except for the postcard, was signed by the study PI (O.S.). As a token of
appreciation, physicians who retuned the survey received a $10 gift card to a retailer of their
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choice. All aspects of the study were approved by the Institutional Review Board at the Virginia
Commonwealth University.
Measures and Variables
E-cigarette recommendations
Our main outcome variable was whether or not the PCP reported previously
recommending e-cigarettes for smoking cessation, harm reduction or both to his/her adult
patients who smoke. We categorized PCPs as “never” versus “ever” recommending e-cigarettes,
regardless of reason for recommendation. We also ascertained PCP-reported e-cigarette
discussion frequency and initiation. For the latter, response categories were: I usually raise the
topic, my patients usually raise the topic, and it is equally as likely that I or my patients raise the
topic. An additional item was used to assess the extent to which PCPs considered patients’
interest in trying e-cigarettes when recommending e-cigarettes by asking whether patient’s
interest is/would be a primary reason for recommending e-cigarettes (Strongly Disagree to
Strongly Agree) and was scored from one to seven.
Knowledge about e-cigarettes
Five items assessed PCPs’ knowledge regarding e-cigarettes. One item assessed whether
e-cigarettes are currently regulated by the FDA. Two were risk-related: the nicotine liquid used
in e-cigarettes can contain carcinogens and e-cigarettes can adversely affect lung function. Two
items were product feature-related: some e-cigarettes can deliver more nicotine than traditional
cigarettes and some e-cigarette brands do not deliver nicotine. Responses were true, false or I
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don’t’ know. For analyses these variables were coded as a three-level categorical variables or as a
binary variable (correct versus otherwise).
Beliefs about e-cigarette
PCPs’ e-cigarette beliefs were assessed using five 7-point Likert scale items (Very
Unlikely to Very Likely). For example, we assessed whether PCPs believed e-cigarettes can help
patients quit smoking. An additional belief item assessed whether the PCP believed e-cigarettes
can create dual tobacco users (Strongly Disagree to Strongly Agree).
We also asked PCPs to rate how harmful e-cigarettes and five other tobacco products are
to the health of their patients using a 7-point Likert scale (Not at All Harmful to Extremely
Harmful). The products were traditional cigarettes; tobacco pipes; waterpipes [hookah or
narghile]; cigars, cigarillos and little cigars; and smokeless tobacco. We constructed 5 items to
assess PCPs’ perceived reduced harm of e-cigarettes relative to these other products by
subtracting their e-cigarette score from each of the other scores. For each constructed item, a
positive score indicated relatively less harm, zero indicated equal harm, and a negative score
indicated relatively more harm. A total relative harm reduction score was produced by summing
the resulting scores across the five items (Cronbach α=0.93).

Counseling self-confidence
PCPs were asked to indicate their confidence in two items: their ability to counsel
patients about tobacco use in general and their ability to counsel patients about e-cigarettes use
by indicating their level of agreement using a 7-point Likert scale (Strongly Disagree to Strongly
Agree).
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Other physician characteristics
The survey included questions regarding PCPs’ practice setting (i.e. practice size, average
number of patients seen per week, and percent of professional time spent providing care to adult
patients). It also included prior training in smoking cessation counseling, whether or not PCPs
had a medical school affiliation, and demographic characteristics (gender, age and year of
residency completion). Information on clinical training (Medical doctor vs Doctor of
Osteopathy), specialty (GIM, FM, and FP), board certification, medical school training (US
versus foreign) and geographic practice region were ascertained from the AMA Masterfile.
Statistical Analysis
Descriptive statistics were used to characterize the sample. Prior to conducting analyses,
we assessed item non-response, finding it not to exceed 3.3%. Nonetheless, M-Plus with full
information likelihood estimation was used for inferential analyses. Differences in physicians
who reported recommending e-cigarettes compared to those who reported not recommending ecigarettes were tested using Chi-square tests and t-tests, as appropriate. For categorical variables
(i.e. knowledge items), when an overall Chi-square test established statistical significance, the
Wald test of parameter constraints was used to test for pairwise differences. For the multiple
logistic regression model testing, we included PCPs’ e-cigarette beliefs, knowledge, and their
consideration of patient interest in trying e-cigarettes, controlling for PCPs’ gender, age, years of
practice, specialty, board-certification, medical school training, geographic location, number of
patients per week, percentage of time providing care to adult patients, practice size, having an
academic affiliation, having had a prior training in smoking cessation counseling, their
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confidence in their ability for tobacco use counselling in general and for e-cigarettes in
particular. Variables were considered statistically significant at p<0.05.
Prior to initiating analyses, the representativeness of PCP respondents in terms of age,
gender, clinical training, specialty and practice region was assessed using z tests of differences in
proportions. No significant differences were found between survey respondents and PCPs in the
AMA Masterfile except for PCPs’ specialty. Survey respondents disproportionately were FP
physicians (57.9% vs. 49.1%) and not GIM physicians (39.2% vs. 48.0%). We therefore used a
post stratification weight (GIM=1.2, FP=0.84, and GP=1) to match the proportions in the AMA
Masterfile.
RESULTS
Sample Characteristics
A total of 328 surveys were returned. Among those, 50 were ineligible (37 not in direct
patient care, seven not in primary care, and six retired). The survey response rate, adjusted for
ineligible cases, was 24%.112 The final weighted sample size was 274 PCPs (Table 2). Most
survey respondents were males (62.9%). Mean years of practice was 19.9 (+11.1). The majority
spent at least half of their time providing care to adult patients (84.5%). Most were board
certified in either GIM or FM (83.2%), and 79% attended medical school in the US.
Approximately a third reported prior training in smoking cessation counseling (33.8%) or had an
affiliation with a medical school (36%). Sample PCPs reported having higher self confidence in
counseling patients on conventional tobacco use (M=6.3) relative to e-cigarettes-related
counseling (M=4.3).
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Table 2: Physician Characteristics: Overall and by E-cigarette Recommendation Status
Physician Characteristic
DEMOGRAPHICS AND CLINCAL
TRAINING
Gender (%)*
Male
Female
Years of Practice (mean, SD)
Age (mean, SD)
Board-certification (%)
Yes
No
Specialty (%)
Family or General Practice
General Internal Medicine
Medical school training (%)
United States
Foreign Medical School
CLINICAL PRACTICE INFORMATION
Geographic region (%)
North-East
South
Midwest
West
Practice Size (%)
1-2
3-10
11 or more
Mean number of patients/week (mean, SD)**
Time providing care to adult patients (%)
Less than 49%
50-75%
More than 75%
Academic Affiliation (%)
Yes
No
TOBACCO USE COUNSELING
CHARACTERISTICS
Trained in smoking cessation counseling (%)
Yes
No
Confidence in ability for tobacco use
counseling in general (mean, SD)
Confidence in ability for e-cigarette use
counseling (mean, SD) ***

All
(N=274)†

Recommenders
(n=155)

Non-Recommenders
(n=114)

62.9
37.1
19.9 (+11.1)
52.2 (+10.7)

68.4
31.6
20.2 (+10.9)
52.1 (+10.6)

55.8
44.2
19.8 (+11.4)
52.4 (+10.7)

83.2
16.8

84.6
15.4

16.8
18.6

52.3
47.7

50.6
49.4

54.4
45.6

79.0
21.0

76.9
23.1

82.5
17.5

17.6
34.4
24.9
23.1

18.1
38.7
22.6
20.6

17.5
29.8
27.2
25.4

33.8
33.7
32.5
81.3 (+35.5)

37.3
33.3
29.4
87.5 (+32.7)

28.6
35.7
35.7
74.5 (+37.4)

15.5
19.5
65.0

12.9
20.1
66.9

18.6
18.6
62.8

36.0
64.0

33.1
66.9

42.0
58.0

33.8
66.2
6.3(+1.1)

30.1
69.9
6.3(+1.1)

39.5
60.5
6.3(+1.0)

4.3(+1.9)

4.6(+1.7)

3.8(+2.2)

† There were 5 missing entries from the recommendation status variable
* Significant difference by gender (χ2=4.48, p=0.034)
** Significant difference by mean number of patients/week (t(263)=-3.03, p=0.003)
*** Significant difference by confidence in e-cigarette counseling (t(263)=-0.78, p=0.001)
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E-Cigarettes Recommendations
Over three-quarters (82.7%, n=220) of PCPs reported previously discussing e-cigarettes
with their patients. Among those, 24.7% (n=51) reported discussing e-cigarettes rarely with their
patients, 53.2% (n=109) reported discussing e-cigarettes sometimes and 22.1% (n=45) reported
discussing them often or almost always. Furthermore, while half of the PCPs reported that
patients usually initiated these discussions (51.2%), 16.2% reported initiating discussions
themselves, with the remainder reporting that discussions were initiated equally as likely by them
or their patients (32.6%).
Overall, 57.8% (n=155) reported previously recommending e-cigarettes to an adult
patient who smoked. Among those recommending e-cigarettes, the majority reported
recommending them for smoking cessation and harm reduction (71.6%, n=111), 18.8% for
smoking cessation only, and 9.6% for harm reduction only. PCPs who reported initiating ecigarette discussions more than or equally as likely as their patients were significantly more
likely to recommend e-cigarettes (84.0%) compared to those who reported that their patients
usually initiated e-cigarette discussions (55.7%) [χ2(1)=19.47, p<.001]. On average PCPs
indicated a moderate level of agreement that their patients’ interest in using e-cigarettes
influenced or would influence their decision to recommend e-cigarettes (mean=4.09, ±1.8), with
those PCPs who recommend e-cigarettes having a significantly higher level of agreement
(mean=4.62, ±1.6) compared to PCPs who do not recommend e-cigarettes [mean=3.33, ±1.9; t
(208.3)

=1.29, p<.001].
As illustrated in Table 2, there were few significant differences between physicians who

recommended and did not recommend e-cigarettes. Recommenders were more likely to be male
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(68.4% vs. 55.8%) and reporting seeing significantly more patients per week (M=87.5 vs. 74.5)
than non-recommenders.
Knowledge about E-cigarettes
Few PCPs (7.6%) answered all 5 knowledge questions correctly. Two-thirds (66.4% and
65.0%, respectively) of PCPs correctly knew that e-cigarettes are not currently regulated by FDA
and that some e-cigarette brands can deliver more nicotine than traditional cigarettes (Table 3),
with the remainder mostly choosing I don’t know (27.2% and 27.8%, respectively). Almost half
of the PCPs answered I don’t not know for the three other knowledge questions: whether the
liquid in e-cigarettes can contain carcinogens, e-cigarettes could adversely affect lung function,
and some e-cigarette brands do not deliver nicotine (44.9%, 54.0% and 47.2%, respectively),
with only one third answering these questions correctly (36.9%, 32.8% and 36.2%, respectively).
Those recommending e-cigarettes were more likely to answer the two risk-related items (i.e., ecigarettes can contain carcinogens and can negatively affect lung function) incorrectly compared
to non-recommenders, but other differences in knowledge were not detected by the PCP’s ecigarette recommendation status.
On the other hand, PCPs were more likely to answer knowledge items correctly versus
otherwise if they had previously discussed e-cigarettes with their patients: 69.5% vs. 41.3%
correct regarding FDA regulation (p<.001), 70.0% vs. 39.1% regarding delivering more nicotine
(p<.001), 40.5% vs. 13.0% regarding e-liquid content (p<.001), 40.9% vs. 15.2% regarding
delivering no nicotine (p=0.001). The one exception was for the lung function question where
there was no statistically significant difference in correct knowledge by the PCPs’ reported
discussion status (33% vs. 26%, p=0.35).
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Table 3: Physician E-cigarette Knowledge Assessment: Overall and by E-cigarette
Recommendation
Response
Assessment (%)
Correct
E-cigarettes are not currently
Incorrect
regulated by the FDA
Don’t Know
Correct
Some e-cigarettes can deliver
more nicotine than traditional
Incorrect
cigarettes
Don’t Know
Correct
The nicotine liquid used in
Incorrect
e-cigarettes can contain
carcinogens
Don’t Know
Correct
E-cigarettes can adversely affect
Incorrect
lung function
Don’t Know
Correct
Some e-cigarette brands do not
Incorrect
deliver nicotine
Don’t Know
¥ All items are stated as factually correct
E-cigarette Knowledge Items¥

ALL
N=270†
66.4
6.4
27.2
65.0
7.1
27.8
36.9
18.3
44.9
32.8
13.2
54.0
36.2
16.6
47.2

Recommenders
n=152
68.4
7.2
24.3
71.2
7.8
20.9
38.4
23.8††
37.7
34.2
19.1††
46.7
44.7
13.8
41.4

Non-recommenders
n=113
63.7
5.3
31.0
56.5
6.2
37.2††
34.8
10.7
54.5
37.1
5.3
63.7
24.8
20.4††
54.9

χ2 pvalue
0.440

0.014*

0.006*

0.002*

0.004*

† There were 5 missing entries from the recommendation status variable
*Statistically significant via χ2 test (3x2)
†† Proportion remained significant via Wald test of parameter constraints at p<0.05 (correct responses was the
reference group).

Beliefs about E-cigarettes
Overall, PCPs tended to agree with three negative beliefs regarding e-cigarettes (Table
4): Mean agreement ratings on a 7-point scale were 5.0 (±1.6) for sustaining nicotine addiction,
4.8 (±1.4) for creating dual tobacco users, and 4.8 (±1.5) for discouraging patients’ use of
conventional cessation medications. Mean agreement ratings were 5.4 (±1.6) for limiting
secondhand smoke exposure, 4.2 (±1.6) for decreasing patients’ cancer risk and 4.0 (±1.6) for
helping smokers quit. In all cases, recommenders held significantly stronger positive beliefs and
weaker negative beliefs compared to non-recommenders. In general, PCPs’ beliefs did not differ
by their having correct knowledge regarding e-cigarette. The exceptions were that PCPs with
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correct knowledge regarding the impact of e-cigarettes on lung function and that e-liquids could
contain carcinogens held significantly weaker belief regarding e-cigarettes potential to reduce
cancer risk (data not shown).
Table 4: Mean Beliefs Ratings Regarding E-cigarette Use Outcomes: Overall and by Ecigarette Recommendation Status
E-cigarettes Use Outcomes
Limit secondhand smoke exposure
to patients’ families and friends
Sustain patients’ nicotine
dependence
Create dual tobacco users
Patients are less likely to use
conventional cessation medications
Decrease patients’ cancer risk
Help patients quit smoking

All
N=273†
Mean (SD)

Recommenders
n=155
Mean (SD)

Non-recommenders
n=113
Mean (SD)

Degrees
of
Freedom

t-test
p-value

5.4 (±1.6)

5.9 (±1.3)

4.7 (±1.7)

201.8a

<.001

5.0 (±1.6)

4.8 (±1.4)

5.2 (±1.7)

213.3a

0.036

4.8 (±1.4)

4.6 (±1.4)

5.1 (±1.4)

266b

0.005

4.8 (±1.5)

4.6 (±1.4)

5.1 (±1.7)

265b

0.011

4.2 (±1.6)

4.7 (±1.5)

3.6 (±1.6)

265b

3.9 (±1.6)

4.6 (±1.3)

3.0 (±1.6)

207.0

<.001
a

<.001

† There were 5 missing entries from the recommendation status variable
a
equal variances not assumed
b
equal variances assumed
SD, Standard Deviation

The mean score for the overall relative e-cigarette harm reduction measure was 8.6
(SD=±6.6, range -5 to 30), indicating an overall perception of relative harm reduction.
Physicians who recommended e-cigarettes on average indicated relatively more harm reduction
from e-cigarettes (M= 10.7, SD=±6.1) compared to those who did not recommend e-cigarettes to
their patients (M= 5.8, SD= ±6.1), (t (262) = -4.9, p <.001).
Logistic Regression Results: Factors Associated with Recommending E-cigarettes
Controlling for other factors, the more a PCP reported considering their patients’ interest
in using e-cigarettes, the more likely they were to have recommended e-cigarettes (Table 5): for
every point increase in agreement with the statement that they consider their patients’ interest,
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the likelihood that they recommended e-cigarettes increased by 31%. Similarly, for every point
increase in a PCP’s belief that e-cigarettes can help in quitting smoking, there was 80% increase
in the likelihood of the physician recommending e-cigarettes and for every point increase in a
PCP’s belief that e-cigarettes limit secondhand smoke exposure for others, there was 45%
increase in the likelihood of the physician recommending e-cigarettes. Likewise, for every point
increase in a PCP’s perception of e-cigarettes’ relative harm reduction compared to other tobacco
products, there was an increased likelihood of the PCP recommending e-cigarette use by 11%.
On the other hand, for every point increase in the PCP’s belief that e-cigarettes would deter
patients from using conventional cessation medication, there was a 22% reduction in the
likelihood they recommend e-cigarettes. No other factors were found to be associated with PCPs’
likelihood of recommending e-cigarettes.
Table 5: Multiple Logistic Regression Results: Factors Associated with Physicians’
Likelihood of Recommending E-cigarettes (N=274)
Standardized
Estimate

Predictor Variables
Physician Consideration of Patients’ Interest in Using
E-cigarettes
Physicians’ E-cigarette Belief
Limit secondhand smoke exposure to patients’ families and friends
Sustain patients’ nicotine dependence
Create dual tobacco users
Patients become less likely to use conventional cessation medications
Decrease patients’ cancer risk
Help patients quit smoking
Perceived relative harm reduction score
Physicians’ E-cigarette Knowledge
E-cigarettes are not currently regulated by the FDA
Correcta
Incorrect
Don’t Know
Some e-cigarettes can deliver more nicotine than traditional cigarettes
Correcta
Incorrect
Don’t Know
Some e-cigarette brands do not deliver nicotine
Correcta
Incorrect
Don’t Know
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OR (95% CI)

Pvalue

0.173

1. 31 (1.09,1.58)

0.01*

0.209
0.021
0.053
-0.131
-0.099
0.336
0.230

1.45 (1.15, 1.83)
1.04 (0.85, 1.27)
1.11 (0.86, 1.45)
0.78 (0.64, 0.95)
0.84 (0.66, 1.06)
1.80 (1.45, 2.24)
1.11 (1.05, 1.16)

0.006*
0.757
0.492
0.031*
0.213
<.001*
0.001*

1
0.019
0.029

1.26 (0.31, 5.05)
1.21 (0.56, 2.56)

0.78
0.68

1
-0.016
-0.207

0.83 (0.09, 6.94)
0.26 (0.12, 0.54)

0.88
0.002*

1
-0.071
-0.093

0.47 (0.21, 1.51)
0.58 (0.30, 1.13)

0.34
0.18

Table 5: Continued
OR (95% CI)

Pvalue

1
0.073
-0.052

1.72 (0.68, 4.38)
0.74 (0.35, 1.55)

0.33
0.51

1
0.077
-0.021

1.92 (0.61, 5.99)
0.88 (0.41, 1.89)

0.34
0.79

-0.017
-0.097
0.075
0.009
0.04
-0.098

0.90 (0.48, 1.68)
0.97 (0.91, 1.04)
1.02 (0.95, 1.09)
1.06 (0.55, 2.02)
1.36 (0.59, 3.14)
0.49 (0.18, 1.31)

0.88
0.53
0.24
0.78
0.51
0.62

1
0.009
0.112
0.11
0.066
-0.003
-0.034
-0.103

1.07 (0.47, 2.43)
1.98 (0.95, 4.13)
2.13 (0.89, 5.06)
1.00 (0.99, 1.01)
0.99 (0.72, 1.35)
0.88 (0.57, 1.35)
0.53 (0.27, 1.03)

0.88
0.12
0.14
0.38
0.96
0.64
0.11

0.021
-0.043
0.079

1.14 (0.63, 2.05)
0.89 (0.70, 1.13)
1.12 (0.94, 1.34)

0.71
0.43
0.25

Standardized
Estimate

Predictor Variables
Physicians’ E-cigarette Knowledge (Continued)
The nicotine liquid used in e-cigarettes can contain carcinogens
Correcta
Incorrect
Don’t Know
E-cigarettes can adversely affect lung function
Correcta
Incorrect
Don’t Know
Physicians’ Demographics and Clinical Training
Gender (Female)
Age in years
Years of practice
Specialty (General Internal Medicine)
Board-certification (Yes)
Medical school training (United States)
Clinical practice information
Geographic region
Midwesta
North-East
South
West
Number of patients/week
Time providing care to adult patientsb
Practice Sizeb
Academic Affiliation (Yes)
Tobacco use counseling characteristics
Trained in smoking cessation counseling (Yes)
Confidence in ability for tobacco use counseling in general
Confidence in ability for e-cigarette use counseling

*Significant p-value (all bolded)
a
Reference Group
b
Ordinal variables
OR, Odds Ratio; CI, Confidence Interval; FDA, United Stated Food and Drug Administration

DISCUSSION
Patient-physician discussions about e-cigarettes are becoming common place in primary
care. Consistent with that reported by others,31-33 PCPs in our sample reported being asked by
their patients about e-cigarettes; however, they were also initiating e-cigarette-related discussions
with their patients. Such discussions are occurring despite many PCPs expressing uncertainty or
incorrect knowledge regarding e-cigarettes. Those recommending e-cigarettes report doing so
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both to help their patients stop smoking and as a harm reduction strategy. While sociodemographic, training and practice setting characteristics did not seem to be associated with a
PCP’s likelihood of recommending e-cigarettes, their consideration of patients’ interest in trying
e-cigarettes and beliefs about the benefits and harms associated with e-cigarette use as well as
beliefs regarding the relative harm of e-cigarettes in comparison to other tobacco/nicotine
products were associated with physician reports of recommending e-cigarettes to their patients
who smoke.
Patient–physician discussions around e-cigarettes assessed in prior studies31-33 accounted
only for the possibility of patients inquiring about e-cigarettes, not that physicians may be
initiating such discussions. A substantial number of PCPs reported initiating e-cigarette
discussions with their patients, and those PCPs who did report initiating such discussions were
also more likely to recommend e-cigarette use to their patients. Because prior studies have not
measured physician initiation of discussions, it is not known if this is a continuation of an
existing practice, or whether PCPs might be becoming more proactive regarding e-cigaretterelated discussions. What is known is that the majority of PCPs report both discussing and
recommending e-cigarettes with their patients—likely at a rate higher than previously has been
reported. 8, 30, 31
The overall knowledge base regarding e-cigarettes that is informing PCP-patient ecigarette discussions and recommendations is highly variable. Although, the FDA regulatory
status has been long communicated via their website,36, 108 scientific journals,59, 60 the lay press
113

, and on some e-cigarette industry websites, 114, 115 one third of PCPs nationwide were still not

aware that the FDA does not currently regulate e-cigarettes. Also, PCPs were unaware that ecigarettes can contain carcinogens or could adversely affect lung function. Such findings imply
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that facts contained in recent position statements published by US medical organizations may not
be reaching PCPs.59, 60 Furthermore, the clear void in knowledge regarding the potential harms
associated with e-cigarettes may be indicative of the influence that industry marketing may be
having, as such marketing tends to focus solely on the potential benefits of e-cigarettes and is
void of any risk communication or transparent product labeling.40, 41, 98, 102-104 Such an influence
could also explain PCPs’ generally correct knowledge that some e-cigarettes can deliver more
nicotine than that found in traditional cigarettes, as this information is also consistent with
current industry marketing messages.19, 96, 116, 117 Since those PCPs who reported prior e-cigaretterelated discussions with their patients were more likely to have had correct e-cigarette-related
information, patients could also potentially be a source of PCPs’ information31 or that those
discussions might serve as a trigger for PCPs to look for e-cigarettes-related information. Thus,
not only could industry marketing be reaching end users of e-cigarettes, but it could be also
directly and indirectly informing PCPs knowledge.31 This is potentially important as PCPs’
knowledge of the potential harms associated with e-cigarettes was associated with weaker beliefs
regarding the potential of e-cigarettes to reduce the risk of cancer. This suggests that informing
PCPs about the potential risk of e-cigarettes could result in less recommendation of e-cigarette
via altering their beliefs. Regardless, it seems that PCPs’ current knowledge base is both
inadequate and not a driving factor behind PCPs’ decisions to recommend e-cigarettes to their
patients who smoke, perhaps due to the limited evidence-based sources of information
available.27, 28, 31
Like prior studies,28, 31-33, 92 we found PCPs generally to have favorable beliefs regarding
the ability of e-cigarettes to assist with both smoking cessation and harm reduction. In fact,
beyond patients’ interest in trying e-cigarettes, only these favorable beliefs towards e-cigarettes
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distinguished recommenders from non-recommenders. Our results clearly illustrate that PCPs are
recommending e-cigarettes to their patients who smoke for both harm reduction and smoking
cessation. Since these beliefs are likely informed by industry marketing109 and not evidencebased information, it seems highly plausible that physician recommendations to use e-cigarettes
will continue to grow in absence of empirical evidence, and their belief that little evidence
exists,109 may even hinder their active looking for e-cigarette-related information.118, 119
Our prior qualitative assessment109 suggested that patients’ interest in using e-cigarettes
was a key factor associated with PCPs’ recommendation of e-cigarette use. Results here further
support this finding. PCPs appear to be adopting a patient-centered approach when
recommending e-cigarettes in that they take the patient’s interest in trying e-cigarettes into
account. As a patient’s involvement in a recommendation generally translates to a higher
likelihood of adherence, 120 it is likely that many such recommendations are translating into ecigarette use. Future studies are needed to assess the impact of PCPs’ recommendations on ecigarette use initiation and smoking cessation/continued nicotine dependence.
Limitations
The response rate, while low, was comparable to other physicians’ surveys,121 including
those recently published on e-cigarettes31-33 and reflective of well-documented declining PCP
responses to mailed surveys.121 Nevertheless, there is a potential for response bias that limits the
generalizability beyond the study sample. Respondents and non-respondents could have differed
in un-measured ways such as their interest in the topic122 or exposure to e-cigarettes discussions
with patients. After weighting, our sample respondents, however, mirrored those in the AMA
Masterfile. Nevertheless, caution should be taken when generalizing results to the national
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population of PCPs since the AMA sample is updated on voluntary basis and PCPs’ related
information might not be up-to-date.
Furthermore, e-cigarette products are diverse and our study did not include examination
of PCPs’ beliefs regarding different e-cigarette types, if any. Likewise, although our survey
content, and thus findings, were informed via in-depth interviews with practicing PCPs,109 there
may be other important unmeasured factors associated with PCPs’ e-cigarette recommendations.
CONCLUSION
Discussions regarding and physician recommendations for e-cigarette use are now
commonplace among primary care office visits. This new norm has occurred despite limited
evidence regarding the potential harms and benefits of e-cigarettes, and despite PCPs
acknowledging their knowledge limitations. Our results illustrate both the importance of rapidly
fostering the development of this knowledge base as well as an opportunity to disseminate what
is currently known to PCPs. Whether altering this knowledge will impact PCPs’
recommendations for e-cigarettes is not known. What is well known, however, is that once
physicians’ practice is established it is difficult to change,99, 123 and currently PCPs in the US—
the frontline for preventive care and tobacco use counseling—are establishing their e-cigarette
practices mostly in absence of knowledge of either the potential harms or benefits of e-cigarette.
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Chapter 4: Factors Associated with Primary Care Physicians’ Intention to
Recommend E-cigarette Use to their Adult Patients Who Smoke
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ABSTRACT
Background: E-cigarette use has been increasing in the United States over the past few years.
Physicians are currently recommending the use of e-cigarettes to their patients for smoking
cessation and harm reduction. Objective: Assess and compare the factors influencing PCPs’
intent to recommend e-cigarette use for patients with different tobacco use profiles. Methods:
Using a modified Dillman approach, we administered a mailed survey to a national random
sample (N=1430) of office-based primary care physicians (PCPs) between February and May,
2015. Survey content and our conceptual model were informed by existing literature and
qualitative research. Paired t-tests were used to compare PCPs’ recommendation intention for
different patient types. M-Plus with full information likelihood estimation was used to test our
conceptual model, and to identify the factors associated with PCPs’ intentions of recommending
e-cigarette use to patients with different tobacco use profiles. Results: We had a 24% response
rate. The overall mean physician recommendation intention was 16.7 (± 9.5, range= 5 to 35).
Intentions were highest for smokers with prior unsuccessful quit attempts (mean=3.63, ±2.1),
followed by heavy smokers wanting to quit (3.57, ±2.2), and heavy smokers refusing to quit
(mean=3.50, ±2.2). The mean for PCPs’ recommendation intentions was 3.04 (±2.0) for light
smokers wanting to quit, and 3.01 (±1.9) for light smokers refusing to quit. The main predictor
variables in our conceptual model were all significantly associated with PCPs’ intentions in
addition to PCPs’ knowledge (R2=0.54, p<.001). PCPs intentions were varied by patient type.
Limitations: There is a potential for response bias which limits the ability to generalize beyond
the sample. Conclusion: PCPs’ intent to recommend e-cigarettes to their adult patients who
smoke is strongly influenced by PCPs’ beliefs as well as PCPs’ consideration of patients’ interest
in using e-cigarettes and their tobacco use profile. This recommendations’ personalization is
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consistent with patient centered care. The impact of PCPs’ practice is not ascertained; however,
it could potentially have negative consequences on the health of their patients unless e-cigarettes
turn out to be an effective cessation aid and/or harm reduction strategy. Future research should
examine e-cigarettes harms and benefits regarding different tobacco use profiles to accommodate
PCPs’ perceptions and practice setting challenges.
Abbreviations
US

United States

PCP

Primary Care Physician

TRA

Theory of Reasoned Action

AMA

American Medical Association
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INTRODUCTION
E-cigarette use has been increasing steadily in the United States (US) over the past few
years.24 Evidence regarding the potential of e-cigarettes for smoking cessation is inconclusive
and their role as a harm reduction strategy is still unknown.29, 45, 46, 54, 59, 60 Nevertheless, a recent
national survey of primary care physicians (PCPs) in the US revealed that more than half of
PCPs are recommending e-cigarettes to their adult patients who smoke.124 The same study found
that PCPs generally believe e-cigarettes could help with smoking cessation and perceive ecigarettes as less harmful than other tobacco products.124
Early studies found that physicians’ beliefs regarding the ability of e-cigarettes to
decrease cancer risk for patients, being younger,32 or being a male physician33 were all factors
associated with physicians’ recommendations for e-cigarette use.31-33 We recently reported
similar findings among a national sample of PCPs.124 That study also found that PCPs report
considering their patients’ expressed interest in trying e-cigarettes and the perceived relative
harm reduction potential of e-cigarettes when recommending their use to patients who smoke.124
Likewise, findings from our own qualitative study suggested that physicians may be considering
their patients’ tobacco use profile when deciding whether to recommend e-cigarette use.109
Despite this prior research, our understanding of the factors influencing PCPs’ e-cigarette use
recommendations remains in its infancy, and to date has not been grounded within an established
theoretical framework. Identifying theory-based and modifiable factors associated with PCPs’
recommendations for e-cigarettes could provide a critical knowledge base to our understanding
of how e-cigarettes are being integrated within clinical practice, and thus enable tobacco control
efforts to be well-poised to impact e-cigarette recommendation behaviors regardless of the
direction in which they may need to be modified pending emerging evidence.125
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Although previous studies have established that the Theory of Reasoned Action (TRA)
provides a useful framework for explaining variability in physician intentions to recommend
treatments to patients, 89, 126-128 to our knowledge no prior study has identified the factors
influencing PCPs’ intent to recommend e-cigarette use to their patients who smoke, or how such
factors may vary across patients with different tobacco use profiles. We address these knowledge
voids by testing the appropriateness of a TRA-informed conceptual model for understanding
PCPs’ intentions to recommend e-cigarette use to their patients who smoke.109, 124 Additionally,
we compare and contrast the factors influencing PCPs’ intent to recommend e-cigarette use for
patients with different tobacco use profiles (i.e. different patient types).
Theory of Reasoned Action Informed Conceptual Model
The TRA129 suggests that attitudes and subjective norms contribute to PCPs’ intentions to
recommend e-cigarettes to their patients who smoke. PCPs’ intentions subsequently shape their
decision as to whether or not to recommend e-cigarettes.87, 130 For TRA testing, attitudes and
subjective norms items are developed via semi-structured interviews. Overall attitudes and
subjective norms measures are created via utilizing the item total scores to account for the
strength of the attitudes and subjective norms held by the person, and the individual items help
understand the different factors driving attitudes and subjective norms to be able to plan effective
TRA-based behavioral interventions.87, 89, 90
The Model of Clinical Decision Making proposes that patient interest in using a specific
treatment have a greater impact on physicians’ decision making when treating a chronic
condition that is not immediately life threatening.91 Given the push to deliver patient-centered
care and the expectation that patient interests play a role in clinician recommendations,91, 131 we
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adapted the TRA to explicitly account for PCPs’ consideration of patients’ interest in trying ecigarettes. Finally, results from our prior research suggested that a PCP’s overall relative harm
reduction perception of e-cigarettes compared to other tobacco products is likely a salient factor
in their decision to recommend e-cigarette use.124
The overall purpose of this study is to test the theoretical tenets of the resulting
conceptual model (Figure 3). To accomplish that, we address two specific research objectives.
First, we test the utility of the TRA in predicting PCPs’ overall intentions to recommend ecigarettes in the expanded TRA-informed conceptual model (adding patient interest and relative
harm reduction to the model) using the total TRA item scores (Objective 1). Upon verifying the
expanded conceptual model, we test the association of all independent variables from our
conceptual model, including the individual items forming the PCPs’ attitudes and subjective
norms, with PCPs’ intentions to recommend e-cigarettes for each patient type and compare
differences in the associations identified (Objective 2).

Figure 3: Model of Physician Intention of E-cigarette use Recommendation
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METHODS
Participants and Data Collection
Using the American Medical Association (AMA) Masterfile, we invited a nationally
representative random sample of N=1,430 general internal medicine, family medicine and
general practice physicians to complete a mailed survey. We used a modified Dillman approach
to administer the survey.111 Physicians received up to two reminders to participate in the study
and received a $10 gift card to a retailer of their choice as a token of appreciation upon returning
the survey. There was no difference between responders and the national AMA pool of
physicians except for the distribution of family medicine and general internal medicine
specialties. Additional information regarding the sample, and survey administration process are
reported elsewhere.124 All aspects of the study were approved by the Institutional Review Board
of the Virginia Commonwealth University.
Questionnaire Development
As previously reported,109 and recommended for constructing TRA-based questionnaire
items,89, 129, 132, 133 we used qualitative semi-structured interviews to elicit salient PCP beliefs
regarding the outcomes associated with, facilitators of, and barriers to recommending ecigarettes to patients who smoke. We also used semi-structured cognitive interviews with 10
PCPs practicing in an academic medical center to pre-test the final survey instrument for clarity
and ease of understanding. Regardless of the wording of the TRA measures’ items, all were
scored in such a way that higher scores represented positive responses toward the intended
behavior (i.e. intent to recommend e-cigarettes to patients who smoke). 87
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For the study’s intention measure, we assessed PCPs’ behavioral self-prediction of
recommending e-cigarettes to different patient types. When measuring clinical practice
recommendation intentions, measuring a physician’s likelihood (i.e. behavioral self-prediction)
of performing the simulated behaviors is known to be a better proxy measure of the behavioral
performance than measuring a physician’s desire towards the overall behavior (i.e.
recommending e-cigarettes in general).90, 134, 135 Measuring intention in such way mimics a “reallife” behavioral situation that more closely approximates complex clinical decisions.90, 134, 135 For
the attitudes and subjective norms, based on cognitive testing of the final survey instrument, their
items were only represented by their belief components and not the evaluative components to
minimize survey burden. Adding the evaluative component for an item when the corresponding
belief component has obviously a positive or negative outcome could be a source of
annoyance,136 which was confirmed via our cognitive interviews. Additionally, prior studies have
found that using the evaluative components added little variance to TRA measures.137, 138
Measures
E-cigarette use recommendation intention
The PCPs’ likelihood of recommending e-cigarettes over the next three months was
ascertained using 7-point Likert scales (Not at All Likely to Very Likely). Based on results from
semi-structured interviews,109 we assessed likelihood for five different patient types: heavy
smokers refusing to quit, heavy smokers wanting to quit, light smokers refusing to quit, light
smokers wanting to quit, and smokers with prior unsuccessful quit attempts. A total intention
score was computed by summing responses across each of the five patient types (Cronbach α
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=0.94). The overall summed score was used for Objective 1. The intention score for each patient
type was used for Objective 2.
Attitudes
We measured attitudes using four items with a 7-point Likert bipolar response scale.
PCPs were invited to indicate the likelihood (Very Unlikely to Very Likely) of their patients’ use
of e-cigarettes resulting in the following: ‘help patients quit smoking,’ ‘decrease their cancer
risk,’ and ‘limit secondhand smoke exposure to patients’ families and friends’ as well as their
agreement (Strongly Agree to Strongly Disagree) with ‘e-cigarette use can create dual tobacco
users.’ A total overall attitude score was computed (Cronbach α=0.84) and used for Objective 1.
The four individual items were used for Objective 2.
Subjective norms
We measured subjective norms using four items with a 7-point Likert bipolar response
scale. We asked PCPs to indicate whether the following groups would disapprove or approve of
their e-cigarette recommendation: ‘specialty physicians to whom I refer my patients,’ ‘the
professional societies to which I belong,’ ‘my primary care physician colleagues,’ and ‘my
patients who smoke.’ A total subjective norm score was computed (Cronbach α =0.71) and used
for Objective 1. The four individual items were used for Objective 2.
Patients’ interest in trying e-cigarettes
We assessed PCPs’ consideration of their patients’ interest in trying e-cigarettes by
asking whether patient’s interest is/would be a primary reason for recommending e-cigarettes.
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Responses were presented on a 7-point Likert scale (Strongly Disagree to Strongly Agree) and
used in all analyses.
Relative harm reduction
To compute an e-cigarette relative harm reduction perception measure we asked
physicians to rate how harmful e-cigarettes and five other tobacco products are to the health of
their patients using a 7-point Likert scale (Not at All Harmful to Extremely Harmful). Tobacco
products considered were traditional cigarettes; tobacco pipes; waterpipes [hookah or narghile];
cigars, cigarillos and little cigars; and smokeless tobacco. We constructed five relative harm
reduction items by subtracting the e-cigarette score from each of the other tobacco product
scores. A total relative harm reduction score was produced by summing the five constructed
items (Cronbach α =0.93). The resulting overall harm reduction score was used in all analyses
with positive scores indicating relatively less harm from e-cigarettes.
Knowledge and other control variables
When testing associations, we controlled for a number of other PCP characteristics,
including e-cigarette knowledge. A knowledge score (range 0-5) was constructed by summing
the number of correct responses the PCP gave to five true/false knowledge questions. These
questions were based on the current literature and expert opinion, 124 and included items such as
‘the nicotine liquid used in e-cigarettes can contain carcinogens’ and ‘some e-cigarettes can
deliver more nicotine than traditional cigarette.’ We also collected information on year of birth
(for age computation), gender, years of clinical experience post training completion, and average
number of patients seen per week.
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Statistical Analysis
Descriptive statistics were used to characterize the sample and intentions of PCPs to
recommend e-cigarettes. We used paired sample t-tests to compare mean PCP recommendation
intention scores by patient types. Although item non-response did not exceed 3.3%, we
nevertheless used M-Plus with full information likelihood estimation for model testing in support
of both objectives. To address Objective 1, we tested a path model reflecting the full conceptual
model (i.e., inclusive of patient interest and relative harm reduction). To address Objective 2, we
used a multivariate, multivariable regression model to simultaneously compare and contrast the
model components associated with physician intention to recommend e-cigarette use to different
patient types. For all analyses, we used post-stratification weights to account for the
disproportionate survey response rate between family physicians and general internal medicine
physicians.124 In all models, we report the standardized estimates of the beta coefficients, and
their p-values as well as the adjusted R2. Variables were considered statistically significant at
p<0.05.
RESULTS
Sample Characteristics
Data from a total of 274 participants were used in the analysis. The survey response rate
adjusted for ineligible cases was 24%.112 The majority of respondents were males (63%). Mean
years of practice was 19.6 (+11.2), mean age was 52.2 (+10.7) years, mean number of patients
seen per week was 81.3 (+35.5), and the mean knowledge score was 2.3 (+1.5) of a possible 5
points. The mean overall total score for the relative e-cigarette harm reduction perception was
8.6 (+9.0, range= -5 to 30) reflecting a perception that e-cigarettes were relatively less harmful
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than other tobacco products. PCPs generally agreed that patient interest in trying e-cigarette
would influence their recommendation decisions (mean=4.1, ±1.8, range 1 to 7). The mean
attitude and subjective norms scores are presented in Table 6.
Table 6: Mean Attitude and Subjective Norm Scores: Individual Items and Overall
(N=274)
Measures

Mean (SD)

Individual attitude items (range: -3 to +3)
Help quit smoking
Limit second-hand smoke exposure
Decrease cancer risk
Create dual tobacco users (reverse scored)
Total Attitudes (range -12 to 12)
Individual subjective norm items (range: -3 to +3)
Specialty physicians
Professional societies
Primary care physician colleagues
Patients who smoke
Total subjective norm (range -12 to 12)

Cronbach’s
alpha

-0.04 (±1.6)
1.39 (±1.6)
0.24 (±1.6)
-0.82(±1.4)
0.77(±4.6)

0.84

-0.33 (±1.2)
-0.50 (±1.2)
-0.33 (±1.3)
0.51 (±1.2)
-0.63(±4.1)

0.71

E-cigarette Recommendation Intentions
The overall mean physician recommendation intention was 16.7 (± 9.5, range= 5 to 35).
Intentions were highest for smokers with prior unsuccessful quit attempts (mean=3.63, ±2.1),
followed by heavy smokers wanting to quit (3.57, ±2.2), and heavy smokers refusing to quit
(mean=3.50, ±2.2). The mean for PCPs’ recommendation intentions was 3.04 (±2.0) for light
smokers wanting to quit, and 3.01 (±1.9) for light smokers refusing to quit. As shown in Table 7,
mean intentions to recommend e-cigarette use for smokers with unsuccessful quit attempts was
not significantly different than that for heavy smokers, but was significantly higher than that for
light smokers, irrespective of the willingness to quit. Similarly, recommendation intention for
heavy smokers was significantly higher than that for light smokers irrespective of the willingness
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to quit. Physicians’ recommendation intentions were not differentiated by the patient’s
willingness to quit, regardless of whether the patient was a heavy or light smoker.
Table 7: Comparison of Physicians’ E-cigarette Recommendation Intentions for Different
Patient Types (N=274)
Patient Type Comparisons

Mean (SD)

Smokers with prior unsuccessful quit attempts

3.63 (±2.1)

vs. Heavy smokers wanting to quit

3.57 (±2.2)

vs. Heavy smokers refusing to quit

3.48 (±2.2)

vs. Light smokers wanting to quit

3.03 (±2.0)

vs. Light smokers refusing to quit

2.99 (±1.9)
3.58 (±2.2)

Heavy smokers wanting to quit
vs. Heavy smokers refusing to quit

3.50 (±2.2)

vs. Light smokers wanting to quit

3.04 (±2.0)
3.58 (±2.2)
3.01 (±1.9)
3.50 (±2.2)

vs. Light smokers refusing to quit
Heavy smokers refusing to quit
vs. Light smokers wanting to quit

3.05 (±2.0)

vs. Light smokers refusing to quit

3.01 (±1.9)
3.04 (±2.0)

Light smokers wanting to quit
vs. Light smokers refusing to quit

3.01 (±1.9)
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T- Statistic

P-value

0.93

0.351

1.87

0.062

6.76

<.001

7.78

<.001

0.95

0.345

5.98

<.001

6.17

<.001

3.92

<.001

5.47

<.001

0.41

0.683

E-Cigarette Use Recommendation Intentions and the Expanded Theory of Reasoned
Action
Results from the path model are shown in Figure 4. The overall PCPs’ intentions to
recommend e-cigarette use was significantly associated with the PCPs’ total attitudes and
subjective norms, consideration of patients’ interest, e-cigarette relative harm perception and ecigarette knowledge (R2=0.54, p<.001). PCPs who had a more favorable attitude towards ecigarettes, believed more strongly in the relative harm reduction ability of e-cigarettes compared
to other tobacco products, perceived that recommending e-cigarettes would be generally
approved of by their salient referents, and had better e-cigarette-related knowledge were more
likely to intend to recommend e-cigarettes to their patients who smoke. Similarly, PCPs who
perceived their patients to be interested in trying e-cigarettes were also significantly more likely
to intend to recommend them to their patients. Upon testing the path model indirect effects, we
found that attitudes mediated the effect of knowledge (β=-0.049, p=0.023) and gender (β=-0.065,
p=0.008) on intentions, relative harm reduction perception mediated the effect of knowledge
(β=-0.052, p=0.007) and gender (β=-0.037, p=0.030) on intentions, and subjective norms
mediated the effect of age (β=-0.082, p=0.016) and years of practice (β=0.073, p=0.025) on
intentions.

64

*p≤.05
**p≤.01
***p≤.001

This is a saturated model. Only significant pathway coefficients are shown.
Figure 4: Conceptual Model Fit Utilizing Observed TRA Measures
Factors associated with E-Cigarette Recommendation Intentions by Patient Types
Results from the multivariate multivariable regression model showed that increased
PCPs’ perception of approval by their PCP colleagues and patients who smoke (two of the social
norm measures) were associated with their intentions to recommend e-cigarette use regardless of
patient type. Increased belief that e-cigarettes could help patients quit smoking (an attitude
measure) was also associated with PCPs’ intentions for all patient types. Furthermore, increased
belief that e-cigarettes decrease cancer risk for smokers and the relative harm reduction potential
of e-cigarettes were associated with increased intentions to recommend e-cigarettes to all patient
types, except for light smokers wanting to quit. Consideration of the patient’s interest in using ecigarettes was significantly associated with physician’s intentions to recommend e-cigarettes for
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smokers with unsuccessful quit attempts, and for light smokers. The PCPs’ e-cigarette
knowledge was generally not significantly associated with their recommendation intention; the
exception was among smokers with prior unsuccessful quit attempts where knowledge was
positively associated with recommendation intent.
Table 8: Multivariate, Multivariable Model Results: Factors Associated with Physicians’
Intent to Recommend E-Cigarettes by Patient Types (N=274)
Patient Type

Heavy Smoker
Refusing to Quit

Heavy Smoker
Wanting to Quit

Light Smoker
Wanting to Quit

Light Smoker
Refusing to Quit

Smokers with
Prior Unsuccessful
Quit Attempts

Explanatory Variables
(A=Attitude), (SN=Subjective Norm)
Help Quitting (A)
Decrease Cancer Risk (A)
Primary Care Physician Colleagues (SN)
Patients Who Smoke (SN)
Relative Harm Reduction of E-cigarettes
Number of Patients Seen per Week
Help Quitting (A)
Decrease Cancer Risk (A)
Specialty Physicians (SN)
Primary Care Physician Colleagues (SN)
Patients Who Smoke (SN)
Relative Harm Reduction of E-cigarettes
Number of Patients Seen per Week
E-cigarette Knowledge
Help Quitting (A)
Primary Care Physician Colleagues (SN)
Patients Who Smoke (SN)
Patient Interest in Using E-cigarettes
Help Quitting (A)
Decrease Cancer Risk (A)
Primary Care Physician Colleagues (SN)
Patients Who Smoke (SN)
Patient Interest in Using E-cigarettes
Relative Harm Reduction of E-cigarettes
Help Quitting (A)
Decrease Cancer Risk (A)
Primary Care Physician Colleagues (SN)
Patients Who Smoke (SN)
Patient Interest in Using E-cigarettes
Relative Harm Reduction of E-cigarettes
Number of Patients Seen per Week
E-cigarette Knowledge

*p-value <.001
Only Significant predictors are presented in the table.
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Standardized
β coefficient
0.267
0.163
0.228
0.147
0.162
0.131
0.214
0.169
-0.154
0.383
0.094
0.209
0.134
0.142
0.259
0.272
0.124
0.189
0.205
0.139
0.316
0.148
0.125
0.156
0.270
0.154
0.316
0.145
0.106
0.209
0.100
0.090

P for β
<.001
0.011
0.014
0.002
0.006
0.003
<.001
0.005
0.018
<.001
0.042
<.001
0.003
0.001
<.001
0.004
0.016
<.001
<.001
0.049
0.001
0.006
0.019
0.017
<.001
0.012
0.001
0.002
0.032
<.001
0.020
0.038

Model’s R
squared

0.487*

0.562*

0.443*

0.417*

0.566*

Discussion
Consistent with the assumptions laid in our Theory of Reasoned Action informed
conceptual model, PCPs’ intentions to recommend the use of e-cigarettes to their patients who
smoke were largely driven by their attitudes and subjective norms.124 Additionally, PCPs’
consideration of patient interest in using e-cigarettes and their relative harm perceptions of ecigarettes were significant drivers as well. However, neither PCPs’ intentions, nor the drivers of
those intentions were uniform across all patient types. Physicians’ intentions to recommend ecigarettes were particularly high among heavy smokers and those with unsuccessful quit attempts
relative to light smokers. Similarly, physicians’ beliefs that e-cigarettes can decrease cancer risk
for patients was significantly associated with their intentions to recommend e-cigarettes for all
patient types except for light smokers wanting to quit. Conversely, consideration of patients’
interest in using e-cigarettes was associated with PCPs’ intentions to recommend e-cigarettes for
light but not for heavy smokers. Such findings are consistent with the finding that e-cigarettes
are being recommended by PCPs for harm reduction33, 124 as well as for smoking cessation, 32, 124
but also illustrate how PCPs’ intent to recommend e-cigarettes may be highly personalized to
specific patient contexts and situations.
Variation in PCPs’ tobacco use counseling recommendations are well established,76, 139141

with PCPs being known to deliver counseling more frequently to heavy smokers.139 PCPs also

tend to recommend higher doses of cessation pharmacotherapies or more intensive behavioral
interventions to help heavy smokers quit.76, 140, 141 The increased intention to recommend ecigarettes for patients perceived to be heavy smokers or those patients who have tried to quit
multiple times, could indicate that e-cigarette recommendations are not yet a standard approach
to tobacco use counseling in primary care but instead one that is being used selectively. Despite
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that fact that the morbidity linked to smoking is comparable regardless of the amount a patient
smokes142 and that that all forms of tobacco use should be avoided completely,62 prior studies
have continually shown PCPs behave differently when targeting “heavy” versus “light”
smokers.76, 140, 141 Our results are no different: PCPs’ intention to recommend e-cigarettes caries
by patient tobacco use. This could mean that e-cigarettes are being incorporated into physician
cessation counseling in the same manner that other cessation aids are used. PCPs’ advice of
different tobacco use counseling treatments has not always been tied to patients’ willingness to
quit,143 which was also observed in PCPs’ recommendation intentions for e-cigarette use. It is
possible that PCPs are incorporating e-cigarettes into their counseling in a way that is similar to
other cessation medications, or that e-cigarettes could be regarded by PCPs as a part of an
intensive counseling approach aiming at improving the likelihood of future cessation attempts
among those unmotivated to quit.140 Whether e-cigarette recommendations are made after
offering recommended evidence-based cessation therapies cannot be known without future
studies.
PCPs appear to be taking a patient-centered approach to e-cigarette recommendations.
We found PCPs’ intent to recommend e-cigarettes—regardless of patient type—to be associated
with their patients’ perceived approval. However, when it comes to PCPs’ consideration of
patient interest in trying e-cigarettes, it was not consistently associated with their
recommendation intention for all patient types. This association was significant for light smokers
and those with unsuccessful quit attempts, but not for heavy smokers. This suggests that, despite
patients being a salient referent for PCPs when making their treatment decisions, once PCPs
perceive smokers to be of higher risk their consideration of patient interest contributes less to
their recommendation decision as they perceive their patient status to warrant immediate
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attention regardless of the patient’s interest.91 This in itself suggests that PCPs’ relatively high
recommendation intention for heavy smokers, not being driven by their patients’ interest, could
be an implicit endorsement for e-cigarettes’ harm reduction potential for heavy smokers. On the
other hand, patients’ interest was a driver for PCPs’ intention to recommend e-cigarette use to
light smokers. Given that patient interest is likely growing because of industry marketing,24, 27, 96
in addition to a growing proportion of light smokers in general,144 it is very likely that PCPs’
intention to recommend e-cigarettes to light smokers, and hence their future recommendations,145
could grow. The likely impact of this personalized approach by PCPs according to patient types
could be assessed in future studies. Specifically, whether such an approach by PCPs might have
its intended results, such as helping patients quit smoking, or possibly unintended results, such as
creating dual tobacco users, needs to be ascertained.
Having accurate e-cigarette knowledge was directly associated with physicians’
intentions to recommend e-cigarettes and was mediated by PCPs’ attitudes and relative harm
reduction perception. This suggests that PCPs who take the time to gather information about ecigarettes could be developing favorable beliefs regarding e-cigarettes. Since evidence-based
information sources continue to be limited for e-cigarettes, it is likely that physicians who seek
information on e-cigarettes are finding industry-sponsored material.31, 124 Such material is
currently unregulated and known to minimize what is known regarding the potential risks
associated with e-cigarette use.30, 146 Consistent with this, our prior research has found PCPs to
be more knowledgeable of the potential benefits of e-cigarettes relative to their potential
harms.124 Thus, not only is research needed to assess the health and other benefits and risks
associated with e-cigarette use, but efforts are needed to help synthesize and disseminate what
little is known about the impact of e-cigarettes, particularly known risks.
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Limitations
We studied PCPs intentions to recommend e-cigarettes, which although likely associated
with, may not translate to their e-cigarette-related recommendations. Future longitudinal studies
are needed to test how PCPs’ intentions would affect their actual recommendation behavior. Care
also should be taken when generalizing findings to other populations of PCPs. As is increasingly
the case with physician surveys,121 we had a relatively low response rate, and respondents and
non-respondents could have differed in un-measured ways such as their interest in the topic122 or
exposure to e-cigarettes discussions with patients. Furthermore, although the sample was drawn
from the AMA Masterfile it may not be representative of the population of PCPs practicing in
the US. However, the response rate was comparable to other physician surveys,121 including
those recently published on e-cigarettes31-33 and we used post-stratification weights to correct for
the known response bias by PCP reported primary specialty.
Furthermore, the available sample size precluded testing individual attitude and
subjective norms items in the path model. Thus, our ability to understand the influence of
specific beliefs and subjective norms is limited. However, the overall measures used had good
internal consistency. Additionally, the patient types used were chosen to mimic clinical practice
situations that PCPs commonly face. They did not, however, fully account for the complex
situations that PCPs could encounter during e-cigarettes related discussions, and thus may have
missed important clinical considerations. Likewise, e-cigarette products are diverse and our
study did not include examination of PCPs’ beliefs regarding different e-cigarette types, if any.
Furthermore, although our survey content, and thus findings, were informed via in-depth
interviews with practicing PCPs,109 there may be other important unmeasured factors associated
with PCPs’ e-cigarette recommendations.
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CONCLUSION
PCPs’ intent to recommend e-cigarettes to their adult patients who smoke is strongly
influenced by their beliefs regarding e-cigarettes, particularly the potential for harm reduction
relative to other tobacco products, and by the social norms influenced by their primary care
colleagues and patients. Consistent with such influential factors, PCPs’ intent to recommend ecigarettes is not uniform across patient types. Instead, PCPs’ are considering specific patient
scenarios characterized by both the amount a patient smokes and their prior failed quit attempts.
While such personalization is consistent with patient centered care, and because PCPs’ intentions
are likely to translate to future recommendations,145, 147 this may help sustain nicotine dependence
or create dual use, among primary care patients that could have otherwise quit completely using
pharmacotherapies that are approved by the US Food and Drug Administration. This may also
cause unknown harms to patients, many of which are potentially heavy smokers already heavily
exposed to known smoking harms, unless e-cigarettes are ultimately identified as an effective
harm reduction strategy. Finally, the e-cigarette related research agenda should examine ecigarettes harms and benefits regarding different patient types to account for PCPs perceptions
and real practice setting challenges.
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Chapter 5: Conclusions

The three studies presented in this dissertation build upon each other. My qualitative
assessment of Primary Care Physicians (PCPs) beliefs and practices regarding the use of ecigarettes by patients who smoke provided the first in-depth study of PCPs’ beliefs and
recommendations pertaining to e-cigarettes. Until now, published literature assessing PCPs’
practices regarding e-cigarettes31-33 has not been informed by a formative step. By stepping back
and conducting this formative research, I was able to gain valuable insights into the dynamics
that occur between PCPs and patients in clinical practice. My formative research yielded several
important results that in turn guided the instrument development, conceptual model, and methods
used in my quantitative research. First, the results provided a provisional understanding of the
attention that PCPs give to e-cigarettes in their routine tobacco use counseling and how the
communication regarding these products tends to occur. They also highlighted the fact that ecigarettes are recommended for both smoking cessation and harm reduction that some PCPs are
proactively raising the topic of e-cigarettes with their patients who smoke, and the general lack
of a knowledge base about e-cigarettes held by most PCPs. There were two important points that
were clear from the interviews: PCPs believe that e-cigarettes are a safer alternative to smoking
combustible tobacco products, and although they did not typically seem to be recommending ecigarette use to their patients, their concerns regarding the potential harms of e-cigarettes are
abandoned in highly addicted patients and those with extensive comorbidities. In other words,
PCPs’ decision to recommend e-cigarettes seemed to be influenced by their patients’ tobacco use
profile and PCPs’ perceived level of addiction of those patients.
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Another important finding was that at least some PCPs seemed to consider their patients’
interest in trying e-cigarettes, suggesting that PCPs adopting a patient centered approach could
be incorporating e-cigarettes into their clinical practice. Nevertheless, these findings were drawn
from a small sample of PCPs practicing in two settings in Virginia. Thus, there was a need to test
the different assumptions and findings in a larger and more diverse sample of PCPs.
Building on these findings, the aims of my second study were to estimate the prevalence
of PCPs who recommend e-cigarettes to their patients as a smoking cessation aid or as a harm
reduction strategy and to identify PCPs’ beliefs, e-cigarette-related knowledge, and other factors
associated with their recommending e-cigarettes to their adult patients who smoke. Through
mailed surveys to a national sample of office-based PCPs, these aims were addressed. Findings
from this study indicated that PCPs’ recommendations of e-cigarettes have become
commonplace in primary care practice settings for smoking cessation as well as for harm
reduction. Furthermore, results from my survey confirmed that PCPs are not only being asked by
their patients about e-cigarettes, as previous studies have indicated, 31-33 but also that PCPs
themselves are initiating such discussions and those who reported initiating discussions were
more likely to recommend e-cigarettes which reflects that there could be some PCPs who
actively advocate for e-cigarette use. PCPs’ recommendations of e-cigarettes to their adult
patients who smoke were mainly associated with having favorable beliefs towards e-cigarettes’
ability to help patients quit smoking, be exposed to less harm than as from other tobacco
products, and reduce second hand smoke exposure to other people. Those PCPs seemed to decide
intuitively rather than factually, given their lack of correct information, which is a common
decision-making process in cases of uncertainty.148 PCPs who reported recommending ecigarettes were also more likely to take patients’ interest in using e-cigarettes in consideration.
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However, PCPs -regardless of whether or not they recommended e-cigarettes to their patients
who smoke- had limited knowledge about the features and potential harms of e-cigarettes, and
often did not know that e-cigarettes are not regulated by the United States Food and Drug
Administration. Collectively, this could mean that PCPs are being influenced by industry
marketing rather than relying on the limited evidence-based sources available regarding ecigarettes. Results from this study, therefore, highlighted the need to disseminate the existing
knowledge regarding the potential harms and benefits of e-cigarettes to PCPs so that they can
accurately discuss e-cigarettes with their patients. Without such knowledge, neither physicians
nor patients can make informed decisions regarding e-cigarette use.
In my last study, I used a conceptual model that was informed by the Theory of Reasoned
Action (TRA); which proposes that physicians’ behavioral intent, in this case the intention to
recommend e-cigarettes to their patients who smoke, is determined by both attitudes and
subjective norms. I supplemented these TRA domains with the domain of patient interest from
the Model of Medical Decision Making and findings from my formative research to predict
PCPs’ intentions to recommend e-cigarettes. This was done using the same physician sample and
cross-sectional survey employed in my second paper. It is important to note that patient interest
in treatment was significant in all of the analysis I performed throughout the dissertation. This
finding illustrates the likely influence of patient preferences in the context e-cigarettes,148 and the
need to better understand how patient beliefs and preferences regarding e-cigarettes are being
formed.
Of interest here were not only the factors that drive physicians overall intent to
recommend e-cigarettes, but whether the intent and the factors behind that intent may vary across
different types of patients. The types of patients considered were classified based on nicotine
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dependence levels (heavy versus light smokers), willingness to quit, and prior quit attempts.
Each of these was identified as a potentially important tobacco use attribute in my formative
research.
The overall PCPs’ intentions to recommend e-cigarette use was significantly associated
with the PCPs’ total attitudes and subjective norms, consideration of patients’ interest, e-cigarette
relative harm perception and e-cigarette knowledge. However, PCPs’ propensity to intend to
recommend e-cigarettes to their patients varied by patient type, as well as the factors fuelling
those intentions. PCPs’ perception of e-cigarettes potential to decrease patients’ cancer risk, as
well as consideration of patients’ interest in trying e-cigarettes differentiated the five patient
types I included in the study. On the other hand, PCPs’ belief that e-cigarettes can help patients
quit smoking was associated with all patient types. While such personalization is consistent with
patient centered care, there could also be unintended consequences like potentially initiating dual
use or sustaining nicotine addiction in patients who are already heavily dependent on nicotine.
Moreover, this variability in recommendation intention by patient type mimics PCPs’ practice
with conventional smoking cessation aids. Despite the fact that being a light smoker does not
carry substantially less risk compared to being a heavy smoker,62 PCPs seem to perceive the risk
to be different, and act accordingly. For example, in my qualitative interviews in phase one, a
PCP mentioned that “ The people who are smoking like a pack a day and really chimneys, I’m
like you want anything that you can do that’s an action that gets in the right direction. So I
usually am pretty encouraging of it in that setting”109. This highlights the perception that
smoking more cigarettes is more harmful than smoking fewer cigarettes per day and therefore
warrants a need to recommend anything including e-cigarettes for this particular population.
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Taken together, findings from these three studies have important implications for both
research and practice. Of particular note is the general lack of what limited factual information
there is regarding e-cigarettes among PCPs. There is a need for comprehensive mapping of
PCPs’ sources of information, as well as their preferred channels of communication, in order to
know how to effectively disseminate e-cigarette information to PCPs. Differences in nicotine
delivery and other features of e-cigarettes might pose complexity for physicians’ information
gathering, and eventually their decision making. As was noted in the second study, the
assessment of the actual impact of a PCP’s recommendation to a patient to use e-cigarettes has
yet to be explored. This seems important as it has been suggested that physician-patient
communication regarding e-cigarettes might be shaping patients’ perception and their decision to
use e-cigarettes.33
My findings also indicated a need for more in-depth research regarding how PCPs are
incorporating e-cigarette recommendations in clinical practice. While results from my
dissertation research indicated clearly that physicians are advocating for the use of e-cigarettes
for some patients, my research was unable to determine whether such recommendations are
being made as first line therapies for particular types of patients or only after other evidencebased therapies have been exhausted. Additionally, I was unable to ascertain whether there are
specific subgroups of patients with whom PCPs are more likely to introduce the idea of trying ecigarettes. Likewise, we have a limited understanding of the dynamics and conversational
context of patient-physician e-cigarette discussions and how those may impact physician
recommendations or patient adherence to those recommendations. PCPs appear to be applying
their usual counseling techniques regarding e-cigarettes, which are routine and familiar. This
approach could misguide patients’ use of such products or render current tobacco use counseling
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ineffective. Finally, there is a need for further studies to better understand the risk and benefit
profile of e-cigarettes in order to inform PCPs and patients alike.
Despite the efforts of some US cities to regulate e-cigarettes use and marketing, there are
no approved or pending regulatory actions as of yet on a country level in the US. Other countries
have taken drastic measures to limit e-cigarette advertising and vaping in public. For example,
the European parliament issued a ban on e-cigarette advertising that is scheduled to go into effect
in the 28 European union countries in 2016.49 PCPs in the US are well positioned to serve as
strong advocates and partners with public health organizations like the American Lung
Association to lobby for quick and strict measures that could eventually limit the exponential
spread of e-cigarette use among smokers and non-smokers. Taking such early stance is important
given that active, or passive, approval of e-cigarettes by PCPs could help spread e-cigarette use
as was the case with conventional cigarettes in the forties and fifties. 149 The current silence from
the regulatory US-authorities, approval of and recommendation by some physicians and the
widespread advertising and marketing of e-cigarettes could be misperceived by the public as a
proof of e-cigarette safety. In fact e-cigarette diffusion mimics that of dietary supplements where
despite the lack of rigorous empirical evidence or FDA regulation150 products are heavily
marketed,151 and PCPs recommend them to their patients.152 The result has been continued use of
these products among US consumers. 151
My results also have immediate practice implications which could be addressed while the
evidence base surrounding the impact of e-cigarettes on patient health and other outcomes
continues to evolve. Collectively, my results pointed to a clear lack of knowledge regarding ecigarettes among PCPs. In particular, there appears to be a void in knowledge regarding known
potential risks and harms associated with e-cigarette use. Existing position statements of clinical
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care organizations in the United States, while silent on many factors pertaining to e-cigarettes, all
advocate for clinicians to discuss available albeit limited evidence with their patients. If
clinicians are not informed of what is currently known regarding both the potential benefits and
harms associated with e-cigarettes, they cannot be in a position to have such conversations and
thus to support their own and their patients’ informed decision making. Such information needs
to be communicated efficiently on a continual basis given the rapidly evolving evidence base.
Additional efforts are needed to correctly inform the public about e-cigarettes to help them make
an informed decision about its use and because it seemed that their perceptions are also shaping
PCPs’ perceptions and decisions.
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Appendix 1: Semi-structured Interviews Consent Form
RESEARCH SUBJECT INFORMATION AND CONSENT FORM
TITLE: Impact of E-cigarettes on Physician Recommendations of Tobacco Use Cessation
Pharmacotherapy in Primary Care
VCU IRB NO.: HM20000547
If any information contained in this consent form is not clear, please ask the study staff to
explain any information that you do not fully understand. You may take home an unsigned copy
of this consent form to think about or discuss with family or friends before making your
decision.
PURPOSE OF THE STUDY
The purpose of this research study is to find out about physicians attitudes and practice
pertaining to tobacco use cessation counseling in primary care practice. You are being asked to
participate in this study because you are a primary care physician.
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT
If you decide to be in this research study, you will be asked to sign this consent form after you
have had all your questions answered and understand what will happen to you.
In this study you will be asked to complete one in-person interview. The interview will last
about 45 minutes to 1 hour. In the interview you will be asked about your practice regarding
tobacco use cessation counseling recommendations and your perspective about cessation aids.

79

The interview will be audio recorded so we are sure to get all the information. The audio
recording will not be shared with others and no names will be recorded on the tape.
Significant new findings developed during the course of the research which may relate to your
willingness to continue participation will be provided to you.
RISKS AND DISCOMFORTS
We do not expect that you will experience any risks or discomforts by participating. If there are
any questions that make you uncomfortable or that you do not want to talk about, you do not
have to answer. You may decide to discontinue the interviews at any time. If you become upset,
the study staff will give you names of counselors to contact so you can get help in dealing with
these issues.
BENEFITS TO YOU AND OTHERS
You may not get any direct benefit from this study, but, the information we learn from
participants in this study may help to improve tobacco use cessation counseling for patients and
physicians in the future.
COSTS
There are no costs for participating in this study other than the time you will spend being
interviewed.
PAYMENT FOR PARTICIPATION
You will receive a $35 gift card as a thank you for your participation in the interview.
ALTERNATIVES
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Taking part in this research study is voluntary. Instead of being in this research study, you have
the following option:
•

Decide not to participate in this research study

CONFIDENTIALITY
Your confidentiality is very important to us. Potentially identifiable information about you will
consist of audio recordings and transcriptions of interviews. Data is being collected for research
purposes only. Your data will be identified by ID numbers, not names, and stored separately
from medical records in a locked research area. All study related documents and audio tapes will
be stored in a secure location until the study has ended and all data analyses is complete. At that
time, all study material will be placed in a secured long term storage facility until it is deemed
appropriate to destroy the study material.
The results of this research study may be presented at meetings or published, but your name will
not ever be used in these presentations or papers.
We will not tell anyone the answers you give us; however, the consent form signed by you may
be looked at or copied for research or legal purposes by Virginia Commonwealth University.
VOLUNTARY PARTICIPATION AND WITHDRAWAL
You do not have to participate in this study. If you choose to participate, you may stop at any
time without any penalty. You may also choose not to answer particular questions that are asked
in the study.
Your participation in this study may be stopped at any time by the study staff without your
consent. The reasons might include:


the study staff thinks it necessary for your health or safety;
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you have not followed study instructions; or



administrative reasons require your withdrawal.

If you are removed from the research study, the research Investigator will explain to you why
you were removed
QUESTIONS
If you have any questions, complaints, or concerns about your participation in this research,
contact:
Omar El Shahawy, MBBCh, MPH (804) 628-2997 or
Jennifer Elston Lafata, PhD (804) 628-3293

The researcher and study staff named above are the best persons to call for questions about your
participation in this study.
If you have any general questions about your rights as a participant in this or any other research,
you may contact:
Office of Research
Virginia Commonwealth University
800 East Leigh Street, Suite 3000
P.O. Box 980568
Richmond, VA 23298
Telephone: (804) 827-2157
Contact this number for general questions, concerns or complaints about research. You may also
call this number if you cannot reach the research team or if you wish to talk with someone else.
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General information about participation in research studies can also be found at
http://www.research.vcu.edu/irb/volunteers.htm.
CONSENT
I have been given the chance to read this consent form. I understand the information about this
study. Questions that I wanted to ask about the study have been answered. My signature says that
I am willing to participate in this study. I will receive a copy of the consent form once I have
agreed to participate.
Participant name printed

Participant signature

Date

________________________________________________
Name of Person Conducting Informed Consent
Discussion / Witness
(Printed)
________________________________________________ ________________
Signature of Person Conducting Informed Consent

Date

Discussion / Witness

________________________________________________ ________________
Principal Investigator Signature (if different from above)
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Date

Appendix 2: Cognitive Interviews Consent Form
RESEARCH SUBJECT INFORMATION AND CONSENT FORM
TITLE: Impact of E-cigarettes on Physician Recommendations of Tobacco Use Cessation
Pharmacotherapy in Primary Care
VCU IRB NO.: HM20000547
SPONSOR: American Lung Association
If any information contained in this consent form is not clear, please ask the study staff to
explain any information that you do not fully understand. You may take home an unsigned copy
of this consent form to think about or discuss with family or friends before making your
decision.
PURPOSE OF THE STUDY
The purpose of this research study is to find out about physicians attitudes and practice
pertaining to tobacco use cessation counseling in primary care practice. You are being asked to
participate in this study because you are a primary care physician.
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT
If you decide to be in this research study, you will be asked to sign this consent form after you
have had all your questions answered and understand what will happen to you.
In this study you will be asked to complete one in-person interview. The interview will last
about 45 minutes to 1 hour. In the interview you will be asked about your understanding of a
series of questions and their relevance regarding tobacco use cessation counseling
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recommendations and how these questions capture your prespective pertaining to cessation aids.
The interview will be audio recorded so we are sure to get all the information. The audio
recording will not be shared with others and no names will be recorded on the tape.
Significant new findings developed during the course of the research which may relate to your
willingness to continue participation will be provided to you.
RISKS AND DISCOMFORTS
We do not expect that you will experience any risks or discomforts by participating. If there are
any questions that make you uncomfortable or that you do not want to talk about, you do not
have to answer. You may decide to discontinue the interviews at any time. If you become upset,
the study staff will give you names of counselors to contact so you can get help in dealing with
these issues.
BENEFITS TO YOU AND OTHERS
You may not get any direct benefit from this study, but, the information we learn from
participants in this study may help to improve tobacco use cessation counseling for patients and
physicians in the future.
COSTS
There are no costs for participating in this study other than the time you will spend being
interviewed.
PAYMENT FOR PARTICIPATION
You will receive a $35 gift card as a thank you for your participation in the interview.
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ALTERNATIVES
Taking part in this research study is voluntary. Instead of being in this research study, you have
the following option:
•

Decide not to participate in this research study

CONFIDENTIALITY
Your confidentiality is very important to us. Potentially identifiable information about you will
consist of audio recordings and transcriptions of interviews. Data is being collected for research
purposes only. Your data will be identified by ID numbers, not names, and stored separately
from medical records in a locked research area. All study related documents and audio tapes will
be stored in a secure location until the study has ended and all data analyses is complete. At that
time, all study material will be placed in a secured long term storage facility until it is deemed
appropriate to destroy the study material.
The results of this research study may be presented at meetings or published, but your name will
not ever be used in these presentations or papers.
We will not tell anyone the answers you give us; however, the consent form signed by you may
be looked at or copied for research or legal purposes by the sponsor of the research, or by
Virginia Commonwealth University.
VOLUNTARY PARTICIPATION AND WITHDRAWAL
You do not have to participate in this study. If you choose to participate, you may stop at any
time without any penalty. You may also choose not to answer particular questions that are asked
in the study.
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Your participation in this study may be stopped at any time by the study staff without your
consent. The reasons might include:


the study staff thinks it necessary for your health or safety;



you have not followed study instructions;



the sponsor has stopped the study; or



administrative reasons require your withdrawal.

If you are removed from the research study, the research Investigator will explain to you why
you were removed
QUESTIONS
If you have any questions, complaints, or concerns about your participation in this research,
contact:
Omar El Shahawy, MBBCh, MPH (804) 628-2997 or
Jennifer Elston Lafata, PhD (804) 628-3293
The researcher and study staff named above are the best persons to call for questions about your
participation in this study.
If you have any general questions about your rights as a participant in this or any other research,
you may contact:
Office of Research
Virginia Commonwealth University
800 East Leigh Street, Suite 3000
P.O. Box 980568
Richmond, VA 23298
Telephone: (804) 827-2157
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Contact this number for general questions, concerns or complaints about research. You may also
call this number if you cannot reach the research team or if you wish to talk with someone else.
General information about participation in research studies can also be found at
http://www.research.vcu.edu/irb/volunteers.htm.
CONSENT
I have been given the chance to read this consent form. I understand the information about this
study. Questions that I wanted to ask about the study have been answered. My signature says that
I am willing to participate in this study. I will receive a copy of the consent form once I have
agreed to participate.
Participant name printed

Participant signature

Date

________________________________________________
Name of Person Conducting Informed Consent
Discussion / Witness
(Printed)
________________________________________________ ________________
Signature of Person Conducting Informed Consent

Date

Discussion / Witness
________________________________________________ ________________
Principal Investigator Signature (if different from above)
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Appendix 3: Survey Instrument

A National Survey of Primary Care
Physicians in the United States
About E-cigarettes

Instructions


We would like to know your opinions and ideas about e-cigarettes. Please answer each
of the following questions whether or not you have previously discussed or
recommended e-cigarettes to your adult patients.



There are no right or wrong answers, we want to know your personal opinion as a
practicing physician.



Questions in this survey pertain to your adult patients who smoke any type of
tobacco. The survey takes approximately 15-20 minutes to complete. Upon return of
your completed survey, you will receive a $10 gift card of your choice as a small “thank
you” for your help with the study.



You may use a pen or pencil to complete this survey.



Please mark your answers as follows:
Correct marking=

Incorrect marking =



Unless instructed otherwise, mark only one answer per item.



Some questions may seem similar, but please answer each question.



Your answers are strictly confidential; please do not put your name on the survey.

Thank you very much for taking the time to complete this survey!

Please return the completed survey in the enclosed stamped
envelope.
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Section One: E-cigarette Discussions and Experiences

1. Have you ever discussed e-cigarettes with your adult patients who smoke?


 No



 Yes  How often have you
discussed e-cigarettes with your
patients?

 Rarely

 Go to question #2

 When you discuss e-cigarettes with your patients, who
usually raises the topic?


I usually raise the topic

 



Sometimes



My patients usually raise the topic

 



Often



It is equally as likely that I or my patients raise the topic

 



Almost always



2. Over the PAST three months, how often have you recommended e-cigarettes to any of your adult
patients who smoke?
Almost
Never
Rarely
Sometimes
Often
Always
For smoking cessation











For harm reduction











3. We are interested in knowing your thoughts about the impact of recommending e-cigarettes to adult
patients who smoke. In general, do you think your recommending e-cigarettes to patients is …..
Harmful


Neither




Valuable
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Good practice





Neither



Worthless

Neither

Pleasant




Neither

Bad Practice




Beneficial


Unpleasant







4. How likely is it that your patients’ use of e-cigarettes would result in each of the following?
Very
Neither Likely
Unlikely
Nor Unlikely

Very
Likely

Sustain their nicotine dependence















Help them to quit smoking















Limit secondhand smoke exposure to their
families and friends















Decrease their cancer risk





















Make patients less likely to use




conventional cessation medications
5. Please indicate your level of agreement with each of the following statements.
Strongly
Disagree

Neither Disagree
Nor Agree

Strongly
Agree

I feel under pressure to recommend
e-cigarettes to my patients















Screening for e-cigarette use is as important
as screening for traditional cigarette use















E-cigarette use can create dual tobacco users















I am concerned about future litigation
if/when I recommend e-cigarettes















Most people who are professionally
important to me recommend e-cigarettes















6. Over the NEXT three months, how likely are you to recommend e-cigarettes to each of the following
types of patients?
Not at All
Very
Likely
Neither
Likely
Heavy smokers refusing to quit















Light smokers wanting to quit















Former smokers with a recent relapse















Smokers with prior unsuccessful quit
attempts















Smokers with COPD















Heavy smokers wanting to quit















Light smokers refusing to quit















Smokers with a previously diagnosed
mental illness
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Section Two: E-cigarettes perceptions
7. Please indicate the extent to which each of the following groups disapprove or approve of your
recommending
e-cigarettes to your patients who smoke.
Disapprove
Neither

Approve

Specialty physicians to whom I refer
my patients















The professional societies to which I
belong















My primary care physician colleagues















My patients who smoke















Most people whose opinion I value in






my profession
8. Please indicate the extent to which you agree or disagree with each to the following statements.
Strongly
Disagree

Neither Agree
Nor Disagree



Strongly
Agree

Whether I recommend e-cigarettes to
my patients, is entirely up to me















I am confident I could recommend
e-cigarettes if I wanted to















Recommending e-cigarettes to my
patients is easy to do















I am confident in my ability to counsel
patients about e-cigarettes use















I am confident in my ability to counsel
patients about tobacco use in general















9. How much does each of the following factors affect the difficulty/ease of you recommending ecigarettes to your patients who smoke?
Makes it
Very
Neutral
Difficult

Makes it
Very
Easy

The current safety standards for
e-cigarettes















Patients’ interest in trying e-cigarettes















Currently available information on
e-cigarettes
Time available for tobacco use
counseling during office visits





























My current knowledge of e-cigarettes















You are now done with two sections! Please keep going.
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Section Three: E-cigarettes in relation to tobacco products and tobacco
dependence treatment
10. How harmful are the following tobacco products to the health of your patients?
Not at All
Harmful

Moderately
Harmful

Extremely
Harmful

Traditional cigarettes















Tobacco Pipes















Waterpipes (Hookah or Narghile)















E-cigarettes















Cigars, Cigarillos and Little cigars















Smokeless tobacco















11. We are interested in your knowledge of e-cigarettes. Please
indicate whether each of the following statements are true or
false

True

False

I Don’t
Know

E-cigarettes are currently regulated by the FDA







Some e-cigarettes can deliver more nicotine than traditional cigarettes







The nicotine liquid used in e-cigarettes contains carcinogens







E-cigarettes do not diminish lung function







Some e-cigarette brands do not deliver nicotine







Thanks, you are almost done with section three!
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12. What is your level of agreement with each of the following statements?
Strongly
Disagree
E-cigarettes are a gateway to smoking among
non-smokers
My patients’ interest in e-cigarettes is/would be
the primary reason for my recommending them
More FDA regulations for e-cigarettes would
encourage me to recommend them

Neither Agree
or Disagree











































13. The following questions are about you.

16.

Strongly
Agree

Yes

No

Have you ever tried traditional cigarettes?





Have you ever tried e-cigarettes?





Have you used any tobacco product within the last 30 days? (check all that apply)


Yes, traditional cigarettes



Yes, e-cigarettes



Yes, other tobacco products



No, but I used to smoke in the past



No, and I have never smoked on a regular basis

17. In general, how much would you trust information about medical topics from each of the following sources?
Not at
All
A Little
Some
A Lot
Peer-reviewed research studies









FDA publications/recommendations









Professional conferences/scientific meetings









Patients’ experiences









The lay press









CDC publications/recommendations









US Preventive Services Task Force
publications/recommendations









Your physician colleagues









Newsletters or other information sent to you from medical
societies to which you belong









Thanks, you are almost done, only two pages left!
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The Next questions are about the patients you deliver care to and how you spend your time in a
typical week.
Write a number in this box

18. During a typical week, approximately how many adult patients do you see?

____________

19. What is the size of your practice?
Solo
practice
20.



Partner
practice



3-5



6 - 10



Which answer represents the most approximate percentage for each of the following?
Less than
None
25%
25-49%

11 or more



50-75%

More
than 75%

How many of the patients you see in a typical week do you consider
to be your regular patients?











During a typical week, approximately how much of your professional
time do you spend providing primary care to adult patients?











More about You
21. Have you ever received formal training in smoking cessation counseling?


Yes



No

22. Do you have an affiliation with a medical school, such as an adjunct, clinical, or other faculty
appointment?


Yes



No

23. What is your gender?


Male



Female

24. What is the year of your birth?

Write in this box

19 ________

25. What is your ethnicity?


Hispanic or Latino



Not Hispanic or Latino
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26. What is your race? (Check all that apply)


 White



 Black/African American

  Asian
  Native Hawaiian/other Pacific Islander
  American Indian/Alaska native
27. In what year did you start practicing medicine, after completing residency or fellowship?
Write in this box

___________

Your Gift Card Selection
28. What kind of gift card would you like?


Amazon



Target

Thank you very much for completing the survey.

Please return the completed survey in the enclosed stamped
envelope.
or mail it to:
Omar El-Shahawy
830 East Main street (9th floor)
Social and Behavioral Health Department
School of Medicine
Virginia Commonwealth University
PO Box 980149
Richmond, VA, 23298
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